

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 38/00, 38/02, C07K 1/00, 5/00, 7/00, 17/00</b>		A1	(11) International Publication Number: <b>WO 96/40191</b> (43) International Publication Date: 19 December 1996 (19.12.96)
(21) International Application Number: <b>PCT/US96/09499</b>		(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IL, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 6 June 1996 (06.06.96)			
(30) Priority Data: <b>481,957 7 June 1995 (07.06.95) US</b>			
(60) Parent Application or Grant (63) Related by Continuation US Filed on 481,957 (CIP) 7 June 1995 (07.06.95)		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): TRIMERIS, INC. [US/US]; Suite 100, Two University Place, Durham, NC 27702-3408 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): JOHNSON, Ross, M. [US/US]; 102 Hazelnut Court, Chapel Hill, NC 27516 (US). LAMBERT, Dennis, M. [US/US]; 101 Centerville Court, Cary, NC 27513 (US).			
(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds, 1155 Avenue of the Americas, New York, NY 10036 (US).			

(54) Title: THE TREATMENT OF HIV AND OTHER VIRAL INFECTIONS USING COMBINATORY THERAPY

(57) Abstract

Novel antiviral combinations for the treatment or prevention of viral infections, in particular, HIV, are disclosed. This new antiviral therapy employs either DP-178 or DP-107, viral fusion inhibitors, in combination with at least one other antiviral therapeutic agent. The combinations of the invention are better than single therapies alone, and in certain cases are synergistic. The use of DP-178 or DP-107 is an ideal therapy to combine with another antiviral, given both the novel mechanism which this therapeutic blocks HIV transmission and the non-toxicity of the therapeutic.

AM

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Larvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

**THE TREATMENT OF HIV AND OTHER VIRAL  
INFECTIONS USING COMBINATORIAL THERAPY**

**1. FIELD OF THE INVENTION**

This is a continuation-in-part of Serial No. 08/481,957,  
5 filed June 7, 1995.

The present invention relates to methods of treating  
viral infections, particularly HIV infection, using novel  
combinational therapy. The novel combinational therapy  
employs either the peptide DP-178, DP-107 or fragments,  
10 analogs and/or homologs thereof, and at least one other  
therapeutic agent.

DP-178 is a peptide corresponding to amino acids 638 to  
673 of the HIV-1<sub>LAI</sub> transmembrane protein (TM) gp41. DP-178  
includes portions, analogs, and homologs of DP-178, all of  
15 which exhibit antiviral activity. Antiviral activity  
includes, but is not limited to, the inhibition of HIV  
transmission to uninfected CD-4+ cells. Further, the  
invention relates to the use of DP-178 and DP-178 fragments  
and/or analogs or homologs as inhibitors of retroviral  
20 transmission, in particular HIV, to uninfected cells, in both  
humans and non-humans. The present invention also relates to  
the antiviral peptide DP-107, a peptide corresponding to  
amino acids 558 to 595 of the HIV-1<sub>LAI</sub> transmembrane protein  
(TM) gp41, that are present in other enveloped viruses. More  
25 specifically, the invention is directed to the use of DP-107,  
fragments and/or analogs or homologs in combination with  
other therapeutic agents to treat viral infections,  
particularly HIV infection. Further, the invention  
encompasses novel pharmaceutical compositions comprising DP-  
30 178 or DP-107 and at least one other therapeutic agent.

**2. BACKGROUND OF THE INVENTION**

**2.1. The Human Immunodeficiency Virus**

The human immunodeficiency virus (HIV) is a pathogenic  
35 retrovirus and the causative agent of acquired immune  
deficiency syndrome (AIDS) and related disorders (Barre-

Sinossi, F. et al., 1983, *Science* 220:868-870; Gallo, R. et al., 1984, *Science* 224:500-503). There are at least two distinct types of HIV: HIV-1 (Barre-Sinossi, F. et al., 1983, *Science* 220:868-870; Gallo, R. et al., 1984, *Science* 224:500-503) and HIV-2 (Clavel, F. et al., 1986, *Science* 233:343-346; Guyader, M. et al., 1987, *Nature* 326:662-669). Further, a large amount of genetic heterogeneity exists within populations of each of these types. Infection of human CD-4+ T-lymphocytes with an HIV virus leads to depletion of the 10 cell type and eventually to opportunistic infections, neurological dysfunctions, neoplastic growth, and untimely death.

HIV is a member of the lentivirus family of retroviruses (Teich, N. et al., 1984; *RNA Tumor Viruses*, Weiss, R. et al., 15 eds., CSH-press, pp. 949-956). Retroviruses are small enveloped viruses that contain a diploid, single-stranded RNA genome, and replicate via a DNA intermediate produced by a virally-encoded reverse transcriptase, an RNA-dependent DNA polymerase (Varus, H., 1988, *Science* 240:1427-1439). Other 20 retroviruses include, for example, oncogenic viruses such as human T-cell leukemia viruses (HTLV-1,-II,-III), and feline leukemia virus. The HIV viral particle consists of a viral core, made up of proteins designated p24 and p18. The viral core contains the viral RNA genome and those enzymes required 25 for replicative events. Myristylated gag protein forms an outer viral shell around the viral core, which is, in turn, surrounded by a lipid membrane envelope derived from the infected cell membrane. The HIV envelope surface glycoproteins are synthesized as a single 160kD precursor 30 protein which is cleaved by a cellular protease during viral budding into two glycoproteins, gp41 and gp120. gp41 is a transmembrane protein and gp120 is an extracellular protein which remains noncovalently associated with gp41, possibly in a trimeric or multimeric form (Hammerkjold, M. and Rekosh, 35 D., 1989, *Biochem. Biophys. Acta* 989:269-280).

HIV is targeted to CD-4+ T lymphocytes because the CD-4 surface protein acts as the cellular receptor for the HIV-1

virus (Dagleish, A. et al., 1984, *Nature* 312: 767-768, Maddon et al., 1986, *Cell* 47:333-348). Viral entry into cells is dependent upon gp120 binding the cellular CD-4+ receptor molecules, while gp41 anchors the envelope 5 glycoprotein complex in the viral membrane (McDougal, J.S. et al., 1986, *Science* 231:382-385; Maddon, P.J. et al., 1986, *Cell* 47:333-348) and thus explains HIV's tropism for CD-4+ cells.

10

## 2.2. HIV Treatment

HIV infection is pandemic and HIV associated diseases represent a major world health problem. Although considerable effort is being put into the successful design of effective therapeutics, currently no curative anti- 15 retroviral drugs against AIDS exist. In attempts to develop such drugs, several stages of the viral life cycle have been considered targets for therapeutic intervention (Mitsuya, H. et al., 1991, *FASEB J.* 5:2369-2381). Intervention could potentially inhibit the binding of HIV to cell membranes, the 20 reverse transcription of HIV RNA genome into DNA or the exit of the virus from the host cell and infection of new cellular targets.

Attempts are being made to develop drugs which can inhibit viral entry into the cell, the earliest stage of HIV 25 infection. Here, the focus has been on CD-4+, the cell surface receptor for HIV. For example, recombinant soluble CD-4 has been shown to block HIV infectivity by binding to viral particles before they encounter CD-4 molecules embedded in cell membranes (Smith, D.H. et al., 1987, *Science* 30 238:1704-1707). Certain primary HIV-1 isolates are relatively less sensitive to inhibition by recombinant CD-4 (Daar, E. et al., 1990, *Ann. Int. Med.* 112:247-253). In addition, recombinant soluble CD-4 clinical trials have produced inconclusive results (Schooley, R. et al., 1990, 35 *Ann. Int. Med.* 112:247-253; Kahn, J.O. et al., 1990, *Ann. Int. Med.* 112:254-261; Yarchoan, R. et al., 1989, *Proc. Vth Int. Conf. on AIDS*, p564, MCP 137).

The virally encoded reverse-transcriptase-targeted drugs, including 2',3'-dideoxynucleoside analogs such as AZT, ddI, ddC, and d4T, have been developed which have also been shown to be active against HIV (Mitsuya, H. et al., 1991, 5 Science 249:1533-1544). While beneficial, these nucleoside analogs are not curative, probably due to the rapid appearance of drug resistant HIV mutants (Lander, B. et al., 1989, Science 243:1731-1734). In addition, the drugs often exhibit toxic side effects such as bone marrow suppression, 10 vomiting, and liver function abnormalities.

The late stages of HIV replication, which involve crucial virus-specific secondary processing of certain viral proteins, have also been suggested as possible anti-HIV drug targets. Late stage processing is dependent on the activity 15 of a viral protease, and drugs are being developed which inhibit this protease (Erikson, J., 1990, Science 249:527-533). The clinical outcome of these candidate drugs is still in question.

---

Attention is also being given to the development of 20 vaccines for the treatment of HIV infection. The HIV-1 envelope proteins (gp160, gp120, gp41) have been shown to be the major antigens for anti-HIV antibodies present in AIDS patients (Barin et al., 1985, Science 228:1094-1096). Thus far, these proteins seem to be the most promising candidates 25 to act as antigens for anti-HIV development. To this end, several groups have begun to use various portions of gp160, gp120, and/or gp41 as immunogenic targets for the host immune systems. See for example, Ivanoff, L. et al., U.S. Pat. No. 5,141,867; Saith, G. et al., WO 92/22, 654; Schafferman, A., 30 WO 91/09,872; Formoso, C. et al., WO 90/07,119. Clinical results concerning these candidate vaccines, however, still remain far in the future.

Recently, double stranded RNAs, which elicit a general immune response, have been used in combination with 35 antivirals such as interferon, AZT and phosphonoformate to treat viral infections. See Carter, W., U.S. Patent No. 4,950,652. In addition, a therapy combining a pyrimidine

nucleoside analog and a uridine phosphorylase inhibitor has been developed for the treatment of HIV, see Sommadossi, J.P. et al., U.S. Patent No. 5,077,280. Although these specific therapies may prove to be beneficial, combination therapy in 5 general has the potential for antagonism as demonstrated in vitro with azidothymidine (AZT) and ribavirin. See U.S. Patent No. 4,950,652. Moreover, combination therapy is potentially problematic given the high toxicity of most anti-HIV therapeutics and their low level of effectiveness. Thus, 10 there is a need for a combination therapy which is effective yet non-toxic.

The present invention provides a novel combination therapy based on the use of viral fusion inhibitors (DP-178 and DP-107, etc.) in combination with other antivirals. DP-15 178 and DP-107 are both novel therapeutics in that they prevent the virus from fusing with the cell, thereby very effectively preventing cell to cell transmission of the virus. In addition, DP-178 and DP-107 have proven to be non-toxic in in vitro studies and in animals. The present 20 invention provides the first reported use of such peptides in combination with another antiviral or any other therapeutic agent.

### 3. SUMMARY OF THE INVENTION

25 The present invention relates to methods of treating or preventing viral infections, in particular HIV infections, in mammals, including humans, by administering an effective amount of DP-178, or a pharmaceutically acceptable derivative thereof in combination with at least one other therapeutic 30 agent.

The present invention also relates to methods of treating or preventing viral infections, in particular HIV infections, in mammals, including humans, by administering an effective amount of DP-107 or pharmaceutically acceptable 35 derivatives thereof in combination with at least one other therapeutic agent.

More specifically, the invention relates to methods of treating or preventing viral infections in mammals, including humans, by administering an effective amount of DP-107, DP-178, or a pharmaceutically acceptable derivative thereof, in combination with at least one other antiviral agent. The invention includes the administration of the active agents, e.g., DP-107, DP-178 or another antiviral either concomitantly or sequentially, including cycling therapy. Cycling therapy involves the administration of a first antiviral compound for a period of time, followed by the administration of a second antiviral compound for a period of time and repeating this sequential administration, i.e., the cycle, in order to reduce the development of resistance to one of the therapies. The invention encompasses combinations of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof and at least one other therapeutic, particularly another antiviral, that are synergistic, i.e., better than either agent or therapy alone.

The invention also encompasses combinations of DP-178, DP-107 or a pharmaceutically acceptable derivative thereof with a least one other antiviral having a different site of action than the viral fusion inhibitor. Such a combination provides an improved therapy based on the dual action of these therapeutics whether the combination is synergistic or additive.

The present invention is also directed to methods of treating or preventing HIV infection in mammals, including humans, by administering an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof in combination with at least one other therapeutic agent, in particular at least one other antiviral.

The novel antiviral combinations of the present invention provide a means of treatment which may not only reduce the effective dose of either drug required for antiviral activity, thereby reducing toxicity, but may also improve the absolute antiviral effect as a result of attacking the virus through multiple mechanisms. Similarly,

the novel antiviral combinations provide a means for circumventing the development of viral resistance to a single therapy, thereby providing the clinician with a more efficacious treatment.

5 Another aspect of the invention encompasses pharmaceutical compositions and formulations for treating or preventing viral infections, in particular HIV infections, wherein said compositions comprise an effective amount of DP-178, DP-107, or a pharmaceutically acceptable derivative 10 thereof, at least one additional therapeutic agent and a pharmaceutically acceptable carrier.

Therapeutic agents to be used in combination with DP-178, DP-107 or a pharmaceutically acceptable derivative thereof encompass a wide variety of known treatments.

15 Preferably, the combinations employ DP-107 or DP-178 in combination with agents with a different mode of attack. Such agents include but are not limited to: antivirals, such as cytokines, e.g., rIFN  $\alpha$ , rIFN  $\beta$ , rIFN  $\gamma$ ; inhibitors of reverse transcriptase, e.g., AZT, 3TC, D4T, ddI, and other 20 dideoxynucleosides or dideoxyfluoronucleosides; inhibitors of viral mRNA capping, such as ribavirin; inhibitors of HIV protease, such as ABT-538 and MK-639; amphotericin B as a lipid-binding molecule with anti-HIV activity; and castanospermine as an inhibitor of glycoprotein processing.

25 Thus, the present invention provides an improved antiviral therapy for treating a broad spectrum of viruses including HIV.

The present invention also provides combinational therapy which yields improved efficacy over either agent used 30 as a single-agent therapy.

In addition, the invention provides combinational therapy which allows for reduced toxicity of DP-178 and DP-107 and/or the therapeutic agent with which the peptides are used; thereby providing a higher therapeutic index.

35 The instant invention provides a combinational therapy which provides a means for circumventing the development of viral resistance to a single therapy.

### 3.1. Definitions

As used herein, the term "viral infection" describes a diseased state in which a virus invades healthy cells, uses the cell's reproductive machinery to multiply or replicate 5 and ultimately lyse the cell resulting in cell death, release of viral particles and the infection of other cells by the newly produced progeny viruses. Latent infection by certain viruses is also a possible result of viral infection.

As used herein, the term "treating or preventing viral 10 infections" means to inhibit the replication of the particular virus, to inhibit viral transmission, or to prevent the virus from establishing itself in its host, and to ameliorate or alleviate the symptoms of the disease caused by the viral infection. The treatment is considered 15 therapeutic if there is a reduction in viral load, decrease in mortality and/or morbidity.

The term "synergistic" as used herein refers to a combination which is more effective than the additive effects of any two or more single agents. A synergistic effect as 20 used herein refers to the ability to use lower amounts (doses) of either single therapy to treat or prevent viral infection. The lower doses result in lower toxicity without reduced efficacy. In addition, a synergistic effect can result in improved efficacy, i.e., improved antiviral 25 activity. Finally, synergy may result in an improved avoidance or reduction of viral resistance against any single therapy. A determination of a synergistic interaction between DP-178 or DP-107, and another therapeutic agent may be based on the results obtained from the antiviral assays 30 described in Section 5.5. The results of these assays are analyzed using Chou and Talalay's combination method (Chou and Talalay, 1984, *Adv. Enzyme Regul.* 22:27-55) and 'Dose-Effect Analysis with Microcomputers' software (Chou and Chou, 1987, software and manual. p19-64. Elsevier Biosoft, 35 Cambridge, UK) in order to obtain a Combination Index. Combination Index values < 1 indicates synergy, values > 1

indicate antagonism and values equal to 1 indicate additive effects.

The results of these assays are also analyzed using the method of Pritchard and Shipman (Pritchard and Shipman, 1990, 5 *Antiviral Research* 14: 181-206). This computer program through three dimensional graphic analysis of the results allows for a determination of a synergistic or antagonistic interaction between the antiviral agents.

The term "pharmaceutically acceptable carrier" refers to 10 a carrier medium that does not interfere with the effectiveness of the biological activity of the active ingredient, is chemically inert and is not toxic to the patient to whom it is administered.

As used herein the term "pharmaceutically acceptable 15 derivative" refers to any homolog, analog, or fragment corresponding to the DP-178 or DP-107 peptides as described in Section 5.1.2. *infra* which exhibits antiviral activity and is relatively non-toxic to the subject.

The term "therapeutic agent" refers to any molecule, 20 compound or treatment, preferably an antiviral, that assists in the treatment of a viral infection or the diseases caused thereby.

Peptides are defined herein as organic compounds comprising two or more amino acids covalently joined by 25 peptide bonds. Peptides may be referred to with respect to the number of constituent amino acids, *i.e.*, a dipeptide contains two amino acid residues, a tripeptide contains three, etc. Peptides containing ten or fewer amino acids may be referred to as oligopeptides, while those with more than 30 ten amino acid residues are polypeptides.

Peptide sequences defined herein are represented by one-letter symbols for amino acid residues as follows:

A (alanine)

R (arginine)

35 N (asparagine)

D (aspartic acid)

C (cysteine)

Q (glutamine)  
E (glutamic acid)  
G (glycine)  
H (histidine)  
5 I (isoleucine)  
L (leucine)  
K (lysine)  
M (methionine)  
F (phenylalanine)  
10 P (proline)  
S (serine)  
T (threonine)  
W (tryptophan)  
Y (tyrosine)  
15 V (valine)

#### 4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Amino acid sequence of DP-178 (SEQ ID:1) derived from HIV<sub>LAI</sub>; DP-178 homologs derived from HIV-1<sub>SF2</sub> (DP-20 185; SEQ ID:3), HIV-1<sub>RF</sub> (SEQ ID:4), and HIV-1<sub>MN</sub> (SEQ ID:5); DP-178 homologs derived from amino acid sequences of two prototypic HIV-2 isolates, namely, HIV-2<sub>rod</sub> (SEQ ID:6) and HIV-2<sub>NIHZ</sub> (SEQ ID:7); control peptides: DP-180 (SEQ ID:2), a peptide incorporating the amino acid residues of DP-178 in a 25 scrambled sequence; DP-118 (SEQ ID:10) unrelated to DP-178, which inhibits HIV-1 cell free virus infection; DP-125 (SEQ ID:8), unrelated to DP-178, was also previously shown to inhibit HIV-1 cell free virus infection (Wild *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:10,537-10,541); DP-116 (SEQ 30 ID:9), unrelated to DP-178 had previously been shown to be negative for inhibition of HIV-1 infection using the cell-free virus infection assay (Wild, *et al.*, 1992, Proc. Natl. Acad. Sci USA 89:10,537-10,541). Throughout the figures, the one letter amino acid code is used.

35 FIG. 2. Inhibition of HIV-1 cell-free virus infection by synthetic peptides. IC<sub>50</sub> refers to the concentration of peptide that inhibits RT production from infected cells by

50% compared to the untreated control. Control: the level of RT produced by untreated cell cultures infected with the same level of virus as treated cultures.

FIG. 3. Inhibition of HIV-1 and HIV-2 cell-free virus infection by the synthetic peptide DP-178 (SEQ ID:1). IC50: concentration of peptide necessary to inhibit RT production by 50% compared to the untreated control. Control: Level of RT produced by untreated cell cultures infected with the same level of virus as treated cultures.

FIG. 4. Cytotoxicity study of DP-178 (SEQ ID:1) and DP-116 (SEQ ID:9) on CEM cells. Cell proliferation data is shown.

FIG. 5A-C. DP178-derived peptide antiviral data. The peptides listed herein were derived from the region surrounding the HIV-1 BRU isolate DP178 region (e.g., gp41 amino acid residues 615-717). In instances where peptides contained DP178 point mutations, the mutated amino acid residues are shown with a shaded background. In instances in which the test peptide has had an amino and/or carboxy-terminal group added or removed (apart from the standard amido- and acetyl-blocking groups found on such peptides), such modifications are indicated.

FIG. 5A. The column to the immediate right of the name of the test peptide indicates the size of the test peptide and points out whether the peptide is derived from a one amino acid peptide "walk" across the DP178 region. The next column to the right indicates whether the test peptide contains a point mutation, while the column to its right indicates whether certain amino acid residues have been added to or removed from the DP178-derived amino acid sequence.

FIG 5B. The column to the immediate right of the test peptide name indicates whether the peptide represents a DP178 truncation, the next column to the right points out whether the peptide contains a point mutation, and the column to its right indicates whether the peptide contains amino acids which have been added to or removed from the DP178 sequence itself.

FIG. 5C. The column to the immediate right of the test peptide name indicates whether the test peptide contains a point mutation, while the column to its right indicates whether amino acid residues have been added to or removed 5 from the DP178 sequence itself.

FIG. 6. DP107 and DP107 gp41 region truncated peptide antiviral data.  $IC_{50}$  as defined in FIG. 5C, and  $IC_{50}$  values were obtained using purified peptides except where marked with an asterisk (\*), in which case the  $IC_{50}$  was obtained 10 using a crude peptide preparation.

FIG. 7. Simian immunodeficiency virus (SIV) TM (fusion) protein DP178-like region antiviral data. "NT", not tested.

15

##### 5. DETAILED DESCRIPTION OF THE INVENTION

The invention relates to methods of treating HIV infection in mammals, including humans which comprises administering an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof and an 20 effective amount of at least one other therapeutic agent.

Preferably, the therapeutic agent is another antiviral agent.

The present method provides an improved treatment for viral infection, specifically HIV infection. Specifically, the invention provides synergistic combinations for the 25 treatment of HIV infection which comprise an effective amount of DP-178, DP-107 or pharmaceutically acceptable derivatives thereof and at least one member of a wide range of antiviral compounds available for the treatment of viral diseases. DP- 178, DP-107 or a pharmaceutically acceptable derivative 30 thereof is preferably used in combination with retrovirus inhibitors, viral protease inhibitors, cytokines or cytokine inhibitors or viral fusion inhibitors. The combinations of the present invention are administered to a patient in an amount sufficient to inhibit viral activity, to inhibit viral 35 expression, or to inhibit viral transmission.

The method of the invention encompasses combination therapy in which DP-178, DP-107 and at least one other

therapeutic agent are administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially, including cycling therapy. Cycling therapy involves the administration of a first 5 antiviral compound for a period of time, followed by the administration of a second antiviral compound for a period of time and repeating this sequential administration, i.e., the cycle, in order to reduce the development of resistance to one of the therapies. The invention also encompasses cycling 10 therapy which comprises the administration of a first peptide of the present invention, followed by another antiviral, followed by another peptide of the present invention, etc., such that both viral fusion inhibitors DP-107 and DP-178 or derivatives thereof are used in combination with other 15 antivirals. The invention also encompasses the use of a combination of the peptides, e.g., DP-107 in combination with DP-178.

Administration of DP-178, DP-107 or a pharmaceutically acceptable derivative thereof and one or more therapeutics 20 "in combination" includes presentations in which both agents are administered together as a therapeutic mixture, and also procedures in which the two agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration 25 "in combination" further includes the separate administration of one of the drugs given first, followed by the second.

The Applicants' novel therapy involves the use of peptides which inhibit viral fusion and cell to cell transmission of the virus in combination with another 30 therapeutic. Without being limited by theory, the present invention is based, in part, on the belief that HIV is believed to be replicating 24 hours a day from the first day of infection. Therefore it may be beneficial to use antiviral treatment at different stages of the viral 35 infection.

The combinations disclosed herein present the first known use of viral fusion inhibitors, acting at the first

stage of viral infection, in combination with antivirals having different targets of action.

The DP-178 and DP-107 site of action is at the surface of the virus, preventing free virus from infecting host cells and cell-cell transmission of the virus. Therefore, without being limited by theory, Applicants believe that DP-178 or DP-107 used in combination with one or more drugs having different targets or mechanisms of action provides either an additive or synergistic effect. The combinations of the present invention are advantageous in that the drugs employed will be used at lower, less toxic concentrations.

Combination therapy may not only reduce the effective dose of a drug required for antiviral activity, thereby reducing its toxicity, but may also improve the absolute antiviral effect as a result of attacking the virus through multiple mechanisms. Finally, the combinations of the present invention also provide a means for circumventing or decreasing the chance of development of viral resistance.

The preferred treatments to be used in combination with DP-178 and/or DP-107 include but are not limited to five different modes of attack on the virus: inhibition of the reverse transcriptase, inhibition of viral mRNA capping, inhibition of the HIV protease, inhibition of protein glycosylation, and inhibition of viral fusion. Agents which employ these modes of attack include, but are not limited to, antivirals, such as cytokines, e.g., rIFN  $\alpha$ , rIFN  $\beta$ , rIFN  $\gamma$ ; inhibitors of reverse transcriptase, such as AZT, 3TC, D4T, ddI, and dideoxyfluoronucleosides; inhibitors of viral mRNA capping, such as ribavarin; inhibitors of HIV protease, such as ABT-538 and MK-639; amphotericin B as a lipid-binding molecule with anti-HIV activity; and castanospermine as an inhibitor of glycoprotein processing.

#### 5.1. Treatment Of HIV With DP-178 Or DP-107

35

##### 5.1.1. DP-178 and DP-107 Peptides

DP-178 and DP-107 are peptides that exhibit potent antiviral activity by inhibiting virus fusion. These

peptides include DP-178, a gp41 derived 36 amino acid peptide, fragments and/or analogs of DP-178, and peptides homologous to DP-178. In addition, these peptides may include peptides exhibiting antiviral activity which are 5 analogous to DP-107, a 38 amino acid peptide, corresponding to residues 558 to 595 of the HIV-1<sub>LA1</sub> transmembrane gp41 protein, and which are present in other enveloped viral proteins. The use of the peptides of the invention as inhibitors of non-human and human and retroviral, especially 10 HIV transmission are detailed herein and in U.S. Patent Application Serial No. 08/073,028, filed June 7, 1993, U.S. Patent Application Serial No. 08/264,531, filed June 23, 1994, U.S. Patent Application Serial No. 08/255,208, filed June 7, 1994, U.S. Patent Application Serial No. 08/360,107, 15 filed December 20, 1994, U.S. Patent Application Serial No. 08/374,666, filed January 27, 1995, U.S. Patent Application Serial No. 08/470,896, filed June 6, 1995, and U.S. Patent Application Serial No. 08/485,264, filed June 7, 1995, which are incorporated by reference herein in their entirety.

20 While not limited to any theory of operation, the following model is proposed to explain the potent anti-HIV activity of DP-178. In the viral protein, gp41, DP-178 corresponds to a putative  $\alpha$ -helix region located in the C-terminal end of the gp41 ectodomain, and appears to associate 25 with a distal site on gp41 whose interactive structure is influenced by the leucine zipper motif, a coiled-coil structure, referred to as DP-107. The association of these two domains may reflect a molecular linkage or "molecular clasp" intimately involved in the fusion process. It may be 30 that the leucine zipper motif is involved in membrane fusion while the C-terminal  $\alpha$ -helix motif serves as a molecular safety mechanism to regulate the availability of the leucine zipper during virus induced membrane fusion.

When synthesized as peptides both DP-107 and DP-178 are 35 potent inhibitors of HIV infection and fusion, probably by virtue of their ability to form complexes with viral gp41 and interfere with its fusogenic process; e.g., during the

structural transition of the viral protein from the native structure to the fusogenic state, the DP-107 and DP-178 peptides may gain access to their respective binding sites on the viral gp41, and exert a disruptive influence.

5 A truncated recombinant gp41 protein corresponding to the ectodomain of gp41 containing both DP-107 and DP-178 domains (excluding the fusion peptide, transmembrane region and cytoplasmic domain of gp41) did not inhibit HIV-1 induced fusion. However when a single mutation was introduced to  
10 disrupt the coiled-coil structure of the DP-107 domain -- a mutation which results in a total loss of biological activity of DP-107 peptides--the inactive recombinant protein was transformed to an active inhibitor of HIV-1 induced fusion. This transformation may result from liberation of the potent  
15 DP-178 domain from a molecular clasp with the leucine zipper, DP-107 domain.

The peptide DP-178 of the invention corresponds to amino acid residues 638 to 673 of the transmembrane protein gp41 from the HIV-1<sub>LAI</sub> isolate, and has the 36 amino acid sequence  
20 (reading from the amino to carboxy terminus):

NH<sub>2</sub>-YTSЛИHSLIEESQNQQEKNEQELLELDKWASLWNWF-COOH (SEQ ID:1)

DP-178 is also described in Applicant's co-pending U.S. Patent Applications Ser. No. 08/470,896, filed June 6, 1995, Ser. No. 08/374,666, filed January 27, 1995, Ser. No. 25 08/264,531, filed June 23, 1994, and Ser. No. 08/255,208, filed June 7, 1994, which are incorporated herein by reference in their entirety.

In addition to the full length DP-178 (SEQ ID:1) 36mer, the peptides of the invention may include truncations of the  
30 DP-178 (SEQ ID:1) peptide which exhibit antiviral activity. Such truncated DP-178 (SEQ ID:1) peptides may comprise peptides of between 3 and 36 amino acid residues (i.e., peptides ranging in size from a tripeptide to a 36-mer polypeptide), and may include but are not limited to those  
35 listed in Tables I and II, below. Peptide sequences in these tables are listed from amino (left) to carboxy (right) terminus. "X" may represent an amino group (-NH<sub>2</sub>) and "Z" may

represent a carboxyl (-COOH) group. Alternatively, as described below, "X" and/or "Z" may represent a hydrophobic group, an acetyl group, a FMOC group, an amido group, or a covalently attached macromolecule.

5 DP-107 is a 38 amino acid peptide corresponding to residues 558 to 595 of HIV-1<sub>LAI</sub> transmembrane (TM) gp41 protein, which exhibits potent antiviral activity. DP-107 is an HIV-1-derived antiviral peptide and may also be found in other, non-HIV-1 envelope viruses. DP-107 is more fully 10 described in Applicant's co-pending U.S. Patent Applications Ser. No. 08/470,896, filed June 6, 1995, Ser. No. 08/374,666, filed January 27, 1995, Ser. No. 08/264,531, filed June 23, 1994, and Ser. No. 08/255,208, filed June 7, 1994, which are incorporated herein by reference in their entirety.

15 Deletions of DP107 or DP178 truncations are also within the scope of the invention. Such deletions consist of the removal of one or more amino acids from the DP107 or DP107-like peptide sequence, with the lower limit length of the resulting peptide sequence being 4 to 6 amino acids. Such 20 deletions may involve a single contiguous or greater than one discrete portion of the peptide sequences. One or more such deletions may be introduced into DP107 or DP107 truncations, as long as such deletions result in peptides which may still be recognized by the 107x178x4, ALLMOT15 or PLZIP search 25 motifs described herein, or may, alternatively, exhibit antifusogenic or antiviral activity, or exhibit the ability to modulate intracellular processes involving coiled-coil peptide structures.

DP107 and DP107 truncations are more fully described in 30 Applicants' co-pending U.S. Patent Application Serial No. 08/374,666, filed January 27, 1995, and which is incorporated herein by reference in its entirety.

TABLE I  
DP-178 (SEQ ID:1) CARBOXY TRUNCATIONS

X-YTS-Z  
 X-YTSL-Z  
 X-YTSLI-Z  
 5 X-YTSLIH-Z  
 X-YTSLIHS-Z  
 X-YTSLIHSL-Z  
 X-YTSLIHSLI-Z  
 X-YTSLIHSLIE-Z  
 X-YTSLIHSLIEE-Z  
 X-YTSLIHSLIEES-Z  
 10 X-YTSLIHSLIEESQ-Z  
 X-YTSLIHSLIEESQN-Z  
 X-YTSLIHSLIEESQNQ-Z  
 X-YTSLIHSLIEESQNQQ-Z  
 X-YTSLIHSLIEESQNQQE-Z  
 X-YTSLIHSLIEESQNQQEK-Z  
 X-YTSLIHSLIEESQNQQEKN-Z  
 X-YTSLIHSLIEESQNQQEKNE-Z  
 15 X-YTSLIHSLIEESQNQQEKNEQ-Z  
 X-YTSLIHSLIEESQNQQEKNEQE-Z  
 X-YTSLIHSLIEESQNQQEKNEQEL-Z  
 X-YTSLIHSLIEESQNQQEKNEQELL-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLE-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEL-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLED-Z  
 20 X-YTSLIHSLIEESQNQQEKNEQELLEDK-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKW-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKWA-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKWAS-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKWASL-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKWASLW-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKWASLWN-Z  
 X-YTSLIHSLIEESQNQQEKNEQELLEDKWASLWNW-Z  
 25 X-YTSLIHSLIEESQNQQEKNEQELLEDKWASLWNWF-Z

The one letter amino acid code is used.

Additionally,

"X" may represent an amino group, a hydrophobic group,  
 including but not limited to carbobenzoyl, dansyl, or T-  
 30 butyloxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-  
 carbonyl (FMOC) group; a macromolecular carrier group  
 including but not limited to lipid-fatty acid conjugates,  
 polyethylene glycol, or carbohydrates.

"Z" may represent a carboxyl group; an amido group; a  
 T-butyloxycarbonyl group; a macromolecular carrier group  
 35 including but not limited to lipid-fatty acid conjugates,  
 polyethylene glycol, or carbohydrates.

TABLE II  
DP-178 (SEQ ID:1) AMINO TRUNCATIONS

5

10

15

20

25

X-NWF-Z  
 X-WNWF-Z  
 X-LWNWF-Z  
 X-SLWNWF-Z  
 X-ASLWNWF-Z  
 X-WASLWNWF-Z  
 X-KWASLWNWF-Z  
 X-DKWASLWNWF-Z  
 X-LDKWASLWNWF-Z  
 X-ELDKWASLWNWF-Z  
 X-LELDKWASLWNWF-Z  
 X-LLELDKWASLWNWF-Z  
 X-ELLELDKWASLWNWF-Z  
 X-QELLELDKWASLWNWF-Z  
 X-EQELLELDKWASLWNWF-Z  
 X-NEQELLELDKWASLWNWF-Z  
 X-KNEQELLELDKWASLWNWF-Z  
 X-EKNEQELLELDKWASLWNWF-Z  
 X-QEKNEQELLELDKWASLWNWF-Z  
 X-NQQEKNEQELLELDKWASLWNWF-Z  
 X-QNQQEKNEQELLELDKWASLWNWF-Z  
 X-SQNQQEKNEQELLELDKWASLWNWF-Z  
 X-ESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-EESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-IEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-LIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-SLIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-HSLIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-IHSLIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-LIHSILIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-SLIHSILIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-TSLIHSILIEESQNQQEKNEQELLELDKWASLWNWF-Z  
 X-YTSLIHSILIEESQNQQEKNEQELLELDKWASLWNWF-Z

The one letter amino acid code is used.

Additionally,

30 "X" may represent an amino group, a hydrophobic group, including but not limited to carbobenzoyl, dansyl, or T-butyloxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-carbonyl group; a macromolecular carrier group including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates.

35 "Z" may represent a carboxyl group; an amido group; a T-butyloxycarbonyl group; a macromolecular carrier group including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates.

### 5.1.2. DP-178 and DP-107 Analogs And Homologs

The antiviral peptides of the invention also include analogs of DP-178 and/or DP-178 truncations which may include, but are not limited to, peptides comprising the DP-178 (SEQ ID:1) sequence, or DP-178 truncated sequence, containing one or more amino acid substitutions, insertions and/or deletions. Analogs of DP-178 homologs, described below, are also within the scope of the invention. The DP-178 analogs of the invention exhibit antiviral activity, and may, further, possess additional advantageous features, such as, for example, increased bioavailability, and/or stability, or reduced host immune recognition.

HIV-1 and HIV-2 envelope proteins are structurally distinct, but there exists a striking amino acid conservation within the DP-178-corresponding regions of HIV-1 and HIV-2. The amino acid conservation is of a periodic nature, suggesting some conservation of structure and/or function. Therefore, one possible class of amino acid substitutions would include those amino acid changes which are predicted to stabilize the structure of the DP-178 peptides of the invention.

Amino acid substitutions may be of a conserved or non-conserved nature. Conserved amino acid substitutions consist of replacing one or more amino acids of the DP-178 (SEQ ID:1) peptide sequence with amino acids of similar charge, size, and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to aspartic acid (D) amino acid substitution. When only conserved substitutions are made, the resulting peptide is functionally equivalent to DP-178 (SEQ ID:1) or the DP-178 peptide from which it is derived. Non-conserved substitutions consist of replacing one or more amino acids of the DP-178 (SEQ ID:1) peptide sequence with amino acids possessing dissimilar charge, size, and/or hydrophobicity characteristics, such as, for example, a glutamic acid (E) to valine (V) substitution.

Amino acid insertions may consist of single amino acid residues or stretches of residues ranging from 2 to 15 amino

acids in length. One or more insertions may be introduced into DP-178 (SEQ ID:1), DP-178 fragments, analogs and/or DP-178 homologs.

Deletions of DP-178 (SEQ ID:1), DP-178 fragments, 5 analogs, and/or DP-178 homologs are also within the scope of the invention. Such deletions consist of the removal of one or more amino acids from the DP-178 or DP-178-like peptide sequence, with the lower limit length of the resulting peptide sequence being 4 to 6 amino acids. Such deletions 10 may involve a single contiguous or greater than one discrete portion of the peptide sequences.

The peptides of the invention may further include homologs of DP-178 (SEQ ID:1) and/or DP-178 truncations which exhibit antiviral activity. Such DP-178 homologs are 15 peptides whose amino acid sequences are comprised of the amino acid sequences of peptide regions of other (*i.e.*, other than HIV-1<sub>LAI</sub>) viruses that correspond to the gp41 peptide region from which DP-178 (SEQ ID:1) was derived. Such viruses may include, but are not limited to, other HIV-1 20 isolates and HIV-2 isolates. DP-178 homologs derived from the corresponding gp41 peptide region of other (*i.e.*, non HIV-1<sub>LAI</sub>) HIV-1 isolates may include, for example, peptide sequences as shown below.

25 NH<sub>2</sub>-YTNTIYTLLEESQNQQEKNEQELLDKWASLWNWF-COOH (DP-185; SEQ ID:3);

NH<sub>2</sub>-YTGIIYNLEESQNQQEKNEQELLDKWANLWNWF-COOH (SEQ ID:4);

30 NH<sub>2</sub>-YTSLIYSLEKSQIQQEKNEQELLDKWASLWNWF-COOH (SEQ ID:5).

SEQ ID:3 (DP-185), SEQ ID:4, and SEQ ID:5 are derived from HIV-1<sub>SP2</sub>, HIV-1<sub>RF</sub>, and HIV-1<sub>MN</sub> isolates, respectively.

Underlined amino acid residues refer to those residues that 35 differ from the corresponding position in the DP-178 (SEQ ID:1) peptide. One such DP-178 homolog, DP-185 (SEQ ID:3),

is described in the Working Example presented in Section 6, below, where it is demonstrated that DP-185 (SEQ ID:3) exhibits antiviral activity. The DP-178 homologs of the invention may also include truncations, amino acid 5 substitutions, insertions, and/or deletions, as described above.

In addition, striking similarities, as shown in FIG. 1, exist within the regions of HIV-1 and HIV-2 isolates which correspond to the DP-178 sequence. A DP-178 homolog derived 10 from the HIV-2<sub>NH2</sub> isolate has the 36 amino acid sequence (reading from amino to carboxy terminus):

NH<sub>2</sub>-LEANISQSLEQAAQIQQEKNMYELQKLNSWDVFTNWL-COOH (SEQ ID:7)

15 Table III and Table IV show some possible truncations of the HIV-2<sub>NH2</sub> DP-178 homolog, which may comprise peptides of between 3 and 36 amino acid residues (i.e., peptides ranging in size from a tripeptide to a 36-mer polypeptide). Peptide sequences in these tables are listed from amino (left) to 20 carboxy (right) terminus. "X" may represent an amino group (-NH<sub>2</sub>) and "Z" may represent a carboxyl (-COOH) group. Alternatively, as described below, "X" and/or "Z" may represent a hydrophobic group, an acetyl group, a Fmoc group, an amido group, or a covalently attached macromolecule, as 25 described below.

TABLE III  
HIV-2<sub>NH2</sub> DP-178 homolog carboxy truncations.

X-LEA-Z  
 X-LEAN-Z  
 X-LEANI-Z  
 5 X-LEANIS-Z  
 X-LEANISQ-Z  
 X-LEANISQS-Z  
 X-LEANISQSL-Z  
 X-LEANISQSLE-Z  
 X-LEANISQSLEQ-Z  
 X-LEANISQSLEQA-Z  
 10 X-LEANISQSLEQAQ-Z  
 X-LEANISQSLEQAQI-Z  
 X-LEANISQSLEQAQIQ-Z  
 X-LEANISQSLEQAQIQQ-Z  
 X-LEANISQSLEQAQIQQE-Z  
 X-LEANISQSLEQAQIQQEK-Z  
 X-LEANISQSLEQAQIQQEKN-Z  
 X-LEANISQSLEQAQIQQEKNM-Z  
 15 X-LEANISQSLEQAQIQQEKNMY-Z  
 X-LEANISQSLEQAQIQQEKNMYE-Z  
 X-LEANISQSLEQAQIQQEKNMYEL-Z  
 X-LEANISQSLEQAQIQQEKNMYELQ-Z  
 X-LEANISQSLEQAQIQQEKNMYELQK-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKL-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLN-Z  
 20 X-LEANISQSLEQAQIQQEKNMYELQKLNS-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSW-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWD-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDV-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDVF-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDVFT-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTN-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNW-Z  
 25 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z

The one letter amino acid code is used.

Additionally,

"X" may represent an amino group, a hydrophobic group,  
 including but not limited to carbobenzoyl, dansyl, or T-  
 30 butyloxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-  
 carbonyl (Fmoc) group; a macromolecular carrier group  
 including but not limited to lipid-fatty acid conjugates,  
 polyethylene glycol, or carbohydrates.

"Z" may represent a carboxyl group; an amido group; a  
 T-butyloxycarbonyl group; a macromolecular carrier group  
 35 including but not limited to lipid-fatty acid conjugates,  
 polyethylene glycol, or carbohydrates.

TABLE IV

HIV-2<sub>NH2</sub> DP-178 homolog amino truncations.

5

10

15

20

25

X-NWL-Z  
 X-TNWL-Z  
 X-FTNWL-Z  
 X-VFTNWL-Z  
 X-DVFTNWL-Z  
 X-WDVFTNWL-Z  
 X-SWDVFTNWL-Z  
 X-NSWDVFTNWL-Z  
 X-LNSWDVFTNWL-Z  
 X-KLNSWDVFTNWL-Z  
 X-QKLNSWDVFTNWL-Z  
 X-LQKLNSWDVFTNWL-Z  
 X-ELQKLNSWDVFTNWL-Z  
 X-YELQKLNSWDVFTNWL-Z  
 X-MYELQKLNSWDVFTNWL-Z  
 X-NMYELQKLNSWDVFTNWL-Z  
 X-KNMYELQKLNSWDVFTNWL-Z  
 X-EKNMYELQKLNSWDVFTNWL-Z  
 X-QEKNMYELQKLNSWDVFTNWL-Z  
 X-QQEKNMYELQKLNSWDVFTNWL-Z  
 X-IQQEKNMYELQKLNSWDVFTNWL-Z  
 X-QIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-AQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-QAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-EQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-LEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-SLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-QSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-SQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-ISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-NISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-ANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-EANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z  
 X-LEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWL-Z

The one letter amino acid code is used.

Additionally,

30 "X" may represent an amino group, a hydrophobic group, including but not limited to carbobenzoyl, dansyl, or T-butyloxycarbonyl; an acetyl group; a 9-fluorenylmethoxy-carbonyl (FMOC) group; a macromolecular carrier group including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates.

35 "Z" may represent a carboxyl group; an amido group; a T-butyloxycarbonyl group; a macromolecular carrier group including but not limited to lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates.

### 5.1.3. Preparation Of DP-178 And DP-107

The peptides of the invention may be synthesized or prepared by techniques well known in the art. See, for example, Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman and Co., NY, which is incorporated herein by reference in its entirety. Short peptides, for example, can be synthesized on a solid support or in solution. Longer peptides may be made using recombinant DNA techniques. Here, the nucleotide sequences encoding the peptides of the invention may be synthesized, and/or cloned, and expressed according to techniques well known to those of ordinary skill in the art. See, for example, Sambrook, *et al.*, 1989, Molecular Cloning, A Laboratory Manual, Vols. 1-3, Cold Spring Harbor Press, NY.

15 The peptides of the invention may alternatively be synthesized such that one or more of the bonds which link the amino acid residues of the peptides are non-peptide bonds. These alternative non-peptide bonds may be formed by utilizing reactions well known to those in the art, and may 20 include, but are not limited to imino, ester, hydrazide, semicarbazide, and azo bonds, to name but a few. In yet another embodiment of the invention, peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy 25 termini, such that, for example, the stability, bioavailability, and/or inhibitory activity of the peptides is enhanced. For example, hydrophobic groups such as carbobenzoyl, dansyl, or t-butyloxycarbonyl groups, may be added to the peptides' amino termini. Likewise, an acetyl 30 group or a 9-fluorenylmethoxy-carbonyl group may be placed at the peptides' amino termini. (See "X" in Tables I to IV, above.) Additionally, the hydrophobic group, t- butyloxycarbonyl, or an amido group may be added to the peptides' carboxy termini. (See "Z" in Tables I to IV, 35 above.) Further, the peptides of the invention may be synthesized such that their steric configuration is altered. For example, the D-isomer of one or more of the amino acid

residues of the peptide may be used, rather than the usual L-isomer. Still further, at least one of the amino acid residues of the peptides of the invention may be substituted by one of the well known non-naturally occurring amino acid residues. Alterations such as these may serve to increase the stability, bioavailability and/or inhibitory action of the peptides of the invention.

Any of the peptides described above may, additionally, have a non-peptide macromolecular carrier group covalently attached to their amino and/or carboxy termini. Such macromolecular carrier groups may include, for example, lipid-fatty acid conjugates, polyethylene glycol, or carbohydrates. The truncations, analogs and homologs of DP-178 and DP-107 are described fully in Applicant's co-pending applications Ser. No. 08/073,028, filed June 7, 1993, Ser. No. 08/264,531, filed June 23, 1994, Ser. No. 08/255,208, filed June 7, 1994 and Ser. No. 08/360,107, filed Dec. 20, 1994, which are incorporated herein by reference in their entirety.

20

#### 5.1.4. Therapeutic Uses Of The Peptides Of The Invention

The DP-178 (SEQ ID:1) peptides of the invention, and DP-178 fragments, analogs, and homologs, exhibit potent antiviral activity. The DP-107-like and DP-178-like peptides 25 of the invention preferably exhibit antiviral activity. As such, the peptides may be used as inhibitors of human and non-human viral and retroviral, especially HIV, transmission to uninfected cells.

The human retroviruses whose transmission may be 30 inhibited by the peptides of the invention include, but are not limited to all strains of HIV-1 and HIV-2 and the human T-lymphocyte viruses (HTLV-I and II). The non-human retroviruses whose transmission may be inhibited by the peptides of the invention include, but are not limited to 35 bovine leukosis virus, feline sarcoma and leukemia viruses, simian immunodeficiency, sarcoma and leukemia viruses, and sheep progress pneumonia viruses.

Non retroviral viruses whose transmission may be inhibited by the peptides of the invention include, but are not limited to human respiratory syncytial virus, canine distemper virus, newcastle disease virus, human parainfluenza 5 virus, and influenza viruses.

The invention further encompasses the treatment of the above retroviral and non-retroviral viruses using the peptides in combination therapy.

10        **5.2. Antivirals To Be Used In Combination With DP-178 Or DP-107**

According to the present invention, DP-178 or DP-107, a virus fusion inhibitor, may be used in combination with other therapeutic agents to enhance its antiviral effect achieved.

15        Preferably DP-178 or DP-107 is used in combination with another antiviral agent. Such additional antiviral agents which may be used with DP-178 or DP-107 include but are not limited to those which function on a different target 20 molecule involved in viral replication, e.g., reverse transcriptase inhibitors, viral protease inhibitors, glycosylation inhibitors; those which act on a different target molecule involved in viral transmission; those which act on a different loci of the same molecule; and those which prevent or reduce the occurrence of viral resistance. One 25 skilled in the art would know of a wide variety of antiviral therapies which exhibit the above modes of activity.

DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can also be used in combination with retrovirus inhibitors, such as nucleoside derivatives.

30        Nucleoside derivatives are modified forms of purine and pyrimidine nucleosides which are the building blocks of RNA and DNA. Many of the nucleoside derivatives under study as potential anti-HIV medications result in premature termination of viral DNA replication before the entire genome 35 has been transcribed. These derivatives lack 3' substituents that can bind to subsequent nucleosides and result in chain termination. Nucleoside derivatives such as 3'azido-3'--

thymidine (AZT) and dideoxyinosine (ddI) have been exploited as inhibitors of HIV-1 replication, both in vitro and in vivo. Nucleoside analogs are the currently the only licensed therapeutics for the treatment of HIV infection and AIDS 5 (Fischl et al, 1987 N. Engl. J. Med. 317, 185-191; Mitsuya and Broder, 1987 Nature 325, 773-778). This class of compounds works by inhibiting reverse transcriptase resulting in a block in cDNA synthesis (Mitsuya and Broder, 1987), these inhibitors work early in the infectious cycle of HIV-1 10 and inhibit integration into T-cell genome. However, AZT therapy leads to development of resistant HIV strains (Larder 1989, 1991, *Ibid.*) and demonstrates toxicity in AIDS patients upon long-term therapy (Fischl et al., 1987, N. Engl. J. Med. 317:185-191; Creagh-Kirk, et al., 1988, J.A.M.A. 15 260:3045-3048).

Further, DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can be used in combination with nucleoside derivatives which include but are not limited to, 2',3'-dideoxyadenosine (ddA); 2',3'-dideoxyguanosine (ddG); 20 2',3'-dideoxyinosine (ddI); 2',3'-dideoxycytidine (ddC); 2',3'-dideoxythymidine (ddT); 2',3'-dideoxy-dideoxythymidine (d4T) and 3'-azido-2',3'-dideoxythymidine (AZT). Alternatively, halogenated nucleoside derivatives may be used, preferably 2',3'-dideoxy-2'-fluoronucleosides 25 including, but not limited to, 2',3'-dideoxy-2'-fluoroadenosine; 2',3'-dideoxy-2'-fluoroinosine; 2',3'-dideoxy-2'-fluorothymidine; 2',3'-dideoxy-2'-fluorocytosine; and 2',3'-dideoxy-2',3'-didehydro-2'-fluoronucleosides including, but not limited to 2',3'-dideoxy-2',3'-didehydro-30 2'-fluorothymidine (Fd4T). Preferably, the 2',3'-dideoxy-2'-fluoronucleosides of the invention are those in which the fluorine linkage is in the beta configuration, including, but not limited to, 2',3'-dideoxy-2'-beta-fluoroadenosine (F-ddA), 2',3'-dideoxy-2'-beta-fluoroinosine (F-ddI), and 2',3'-dideoxy-2'-beta-fluorocytosine (F-ddC). Such combinations 35 allow one to use a lower dose of the nucleoside derivative thus reducing the toxicity associated with that agent,

without loss of antiviral activity because of the use of the antiviral peptides. Moreover, such a combination reduces or avoids viral resistance.

Preferred combinations of antiviral peptides and 5 nucleoside derivatives within the scope of the present invention include an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of AZT to treat HIV infection; and an effective amount of DP-107, DP-178 or a pharmaceutically 10 acceptable derivative thereof and an effective amount of ddI.

According to the present invention, DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can also be used in combination with uridine phosphorylase inhibitors, including but not limited to acyclouridine compounds, 15 including benzylacyclouridine (BAU); benzyloxybenzylacyclouridine (BBAU); aminomethyl-benzylacyclouridine (AMBAU); aminomethyl-benzyloxybenzylacyclouridine (AMB-BAU); hydroxymethyl-benzylacyclouridine (HMBAU); and hydroxymethyl-20 benzyloxybenzylacyclouridine (HMBBAU).

According to the present invention, DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can also be used in combination with cytokines or cytokine inhibitors, including but not limited to rIFN  $\alpha$ , rIFN  $\beta$ , rIFN  $\gamma$ , 25 inhibitors of TNF $\alpha$ , and MNX-160. Human rIFN- $\alpha$ A ( $>108$  IU/mg) and rIFN  $\gamma$  ( $1.4 \times 108$  IU/mg) can be obtained from Hoffman LaRoche. Human rIFN  $\beta$  Ser 17 ( $1.0 \times 108$  IU/mg) are obtained from Triton Biosciences. Reference standards are obtained from the World Health Organization (human IFN $\alpha$  WHO standard 30 B,69,19 and human IFN  $\beta$ , WHO no. G-023-902-527, or the National Institute of Allergy and Infectious Disease (human  $\gamma$ , National Institute of Health no. G-023-901-530.

According to the present invention, DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can be used 35 in combination with viral protease inhibitors, including but not limited to, MK-639 (Merck), Invirase (saquinavir, Roche), ABT-538 (Abbott, CAS Reg. No. 155213-67-5), AG1343, VX0478

(Burroughs Wellcome/Glaxo, CAS Reg. No. 161814-49-9), DMP450, SC-52151 (Telinavir). Protease inhibitors are generally thought to work primarily during or after assembly (*i.e.*, viral budding) to inhibit maturation of virions to a mature 5 infectious state. For example, ABT-538 has been shown to have potent antiviral activity *in vitro* and favorable pharmokinetic and safety profiles *in vivo* (Ho, et al., 1995, Nature 373: 123-126). Administration of ABT-538 to AIDS patients causes plasma HIV-1 levels to decrease exponentially 10 and CD4 lymphocyte counts to rise substantially. The exponential decline in plasma viraemia following ABT-538 treatment reflects both the clearance of free virions and the loss of HIV-1 producing cells as the drug substantially blocks new rounds of infection. ABT-538 treatment reduces 15 virus-mediated destruction of CD4 lymphocytes. Combining this treatment with DP-178 and/or DP-107, which inhibits at an earlier stage of HIV infection, viral fusion, would be likely to have synergistic effects and have a dramatic clinical impact.

20 DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can also be used in combination with a class of anti-HIV drugs which interfere with 5'-mRNA processing, for example ribavirin. (Ribavirin (Virazole) from Viratek Inc.). Although the mechanism of action of ribavirin 25 is not clear, this drug is thought to compete with guanosine in the formation of mRNA cap structures and/or interfere with the functional methylation of these molecules. These viruses which may escape the inhibition of viral fusion by DP-178 and/or DP-107 would be blocked by ribavirin and thereby 30 exhibiting synergy of the anti-HIV mechanism of DP-178 and/or DP-107 and ribavirin.

In addition, DP-178, DP-107 or a pharmaceutically acceptable derivative thereof can be used in combination with therapeutic agents, such as Amphotericin B (Fungizone, 35 obtained from Gibco) a polyene microlide antifungal antibiotic which interacts with sterols and binds to them irreversibly. Amphotericin B represents a unique class of

agents that are active against a variety of lipid -enveloped viruses, including HIV. Although amphotericin exhibits severe in vivo toxicities, the methyl ester form of this drug also exhibits anti-HIV activity and has a low cellular 5 toxicity profile in vitro. Therefore amphotericin B or its methyl ester can be used in combinational therapy with DP-178, DP-107 or a pharmaceutical derivative thereof. This combination allows the clinician to employ a lower i.e., less toxic dose of ether Amphotericin B or its methyl ester 10 without concern for loss of antiviral activity since it is used in conjunction with the antiviral peptides DP-178 or DP-107.

According to the present invention, DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof can also be 15 used in combination with inhibitors of glycoprotein processing, such as castanospermine (Boehringer Mannheim). Castanospermine is a plant alkaloid which inhibits glycoprotein processing, and acts as an anti-HIV since HIV contains two heavily glycosylated proteins, gp120 and gp41. 20 Protein glycosylation plays an important role in gp120 interaction with CD4. Under conditions of infection by progeny virions synthesized in the presence of castanospermine the infectivity of HIV was attenuated. Therefore it is likely that DP-178, DP-107 or a 25 pharmaceutically acceptable derivative thereof in combination with castanospermine would act synergistically to inhibit viral entry and hence attenuate infection.

Preferred combinations to be used within the methods of treating HIV include the use of an effective amount of DP-30 107, DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of ddI; the use of an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of 3TC; and the use of an effective amount of DP-107, DP-178 or a 35 pharmaceutically acceptable derivative thereof and an effective amount ribavirin.

A further preferred combinations to be used within the methods of treating HIV include the use of an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of beta-5 interferon.

Yet another combination to be used with the methods of treating HIV include the use of an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of protease inhibitors.

10 In order to evaluate potential therapeutic efficacy of DP-178, DP-107 or a pharmaceutically acceptable derivative thereof in combination with the antiviral therapeutics described above, these combinations may be tested for antiviral activity according to methods known in the art.

15 For example, the ability of a DP-178 and AZT combination to inhibit HIV cytotoxicity, syncytia formation, reverse transcriptase activity, or generation of viral RNA or proteins may be tested in vitro, as described in Example 6.

20 5.2.1. Therapeutic Uses Of HIV-Inhibitory Combinations

The improved or synergistic DP-178 or DP-107 combination therapy as described above may be used in accordance with the invention in vivo to prevent the formation of syncytia and the production of HIV virions and, thus, inhibit the progression of HIV within an exposed patient. The combinational therapy of the present invention is also useful to alleviate or treat disease associated with HIV-infected immunosuppressed patients. For example, the antiviral peptides DP-178, DP-107 or pharmaceutically acceptable derivatives thereof may be used in combination with antifungal agents, antivirals effects against HBV, EBV, CMV, and other opportunistic infections including TB.

The antiviral peptide of the present invention, DP-178, DP-107 or pharmaceutically acceptable derivatives thereof are preferably used against HIV infection. Effective doses of the combination therapy as described below may be formulated in suitable pharmacological carriers and may be administered

by any appropriate means including but not limited to injection (e.g., intravenous, intraperitoneal, intramuscular, subcutaneous, etc.), by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and vaginal epithelial linings, nasopharyngeal mucosa, intestinal mucosa, etc.); orally, transdermally or any other means available within the pharmaceutical arts.

10                   5.3. Pharmaceutical Formulations, Dosages  
And Modes Of Administration

15                   5.3.1. Pharmaceutical Compositions

15                   The pharmaceutical compositions of the invention which are useful in the treatment or prevention of viral infections in humans contain as an active agent DP-178, DP-107 or a pharmaceutically acceptable derivative thereof, and at least one other therapeutic agent, such as another antiviral. The pharmaceutical compositions of the present invention provide combinational therapy that may have either additive and/or synergistic effects.

20                   Preferably, the pharmaceutical compositions containing DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof also contain at least one other antiviral agent, such as reverse transcriptase inhibitors, protease inhibitor, inhibitors of mRNA processing, inhibitors of protein glycosylation and inhibitors of viral fusion. Such agents include but are not limited to nucleoside analogs or chain terminators (e.g., dideoxynucleosides).

25                   Additional suitable therapeutic agents which may be used in combinational therapy with DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof within the scope of the invention include but are not limited to 2-deoxy-D-glucose (2-dGlc), deoxynojirimycin, acycloguanosine, ribavirin (virazole), rifampicin (rifadin), adamanidine, rifabutine, ganciclover, (DHPG), fluoroiodoaracytosine, 30                   idoxurine, trifluorothymidine, adenine arabinoside (ara-A), ara-AMP, bromovinyldeoxyuridine, bromovinylauracil (BV-araU by Bristol-Meyers Squibb (1-beta-D-arabinofuranoside-E-5-[2-

bromovinyl] uracil)) rimantadine, arildone, diarylamidine, (S)-(p-nitrobenzyl)-6-thiocinosine and phosphonoformate.

Novel pharmaceutical compositions encompassed by the present invention include but are not limited to DP-178, DP-5 107 or a pharmaceutically acceptable derivative, and rifampicin (rifadin); DP-178 or DP-107 and AZT; DP-178 or DP-107 and ddi; DP-178 or DP-107 and ddC; DP-178 or DP-107 and adamantidine; DP-178 or DP-107 and acycloguanosine; DP-178 or DP-107 and 2-deoxy-D-glucose; DP-178 or DP-107 and 10 deoxynojirimycin; DP-178 or DP-107 and interferon- $\alpha$  and DP-178 or DP-107 and ganciclovir. The present invention also encompasses pharmaceutical compositions which contain DP-178 or DP-107, or a pharmaceutically acceptable derivative, and optionally more than one additional therapeutic compound.

15 The peptides of the invention may be administered using techniques well known to those in the art. Preferably, agents are formulated and administered systemically.

Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences", 18th ed., 1990, Mack

20 Publishing Co., Easton, PA. Suitable routes may include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, 25 or intraocular injections, just to name a few. Most preferably, administration is intravenous. For injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological 30 saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

In addition, the peptides may be used as a prophylactic 35 measure in previously uninfected individuals after acute exposure to an HIV virus. Examples of such prophylactic use of the peptides may include, but are not limited to,

prevention of virus transmission from mother to infant and other settings where the likelihood of HIV transmission exists, such as, for example, accidents in health care settings wherein workers are exposed to HIV-containing blood 5 products. The peptides of the invention in such cases may serve the role of a prophylactic vaccine, wherein the host raises antibodies against the peptides of the invention, which then serve to neutralize HIV viruses by, for example, inhibiting further HIV infection. Administration of the 10 peptides of the invention as a prophylactic vaccine, therefore, would comprise administering to a host a concentration of peptides effective in raising an immune response which is sufficient to neutralize HIV, by, for example, inhibiting HIV ability to infect cells. The exact 15 concentration will depend upon the specific peptide to be administered, but may be determined by using standard techniques for assaying the development of an immune response which are well known to those of ordinary skill in the art. The peptides to be used as vaccines are usually administered 20 intramuscularly.

The peptides may be formulated with a suitable adjuvant in order to enhance the immunological response. Such adjuvants may include, but are not limited to mineral gels such as aluminum hydroxide; surface active substances such as 25 lysolecithin, pluronic polyols, polyanions; other peptides; oil emulsions; and potentially useful human adjuvants such as BCG and *Corynebacterium parvum*. Many methods may be used to introduce the vaccine formulations described here. These methods include but are not limited to oral, intradermal, 30 intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes.

Effective dosages of the peptides of the invention to be administered may be determined through procedures well known to those in the art which address such parameters as 35 biological half-life, bioavailability, and toxicity. Given the data presented below in Section 6, DP-178, for example,

may prove efficacious in vivo at doses required to achieve circulating levels of 10ng per ml of peptide.

### 5.3.2. Dosage

5 In treating mammals, including humans, having a viral infection a therapeutically effective amount of DP-178, DP-107 or a pharmaceutically acceptable derivative is administered, i.e., a dose sufficient to inhibit viral replication. For example DP-178 or DP-107 may be 10 administered as an infusion at about 0.1 mg/kg to 1.0 mg/kg per day for about 12 weeks. A preferable dose is from 20 mg to 35 mg; the equivalent daily dose of DP-178 or DP-107 or a pharmaceutically acceptable derivative thereof based on surface area is from about 7 mg to 70 mg. The most preferred 15 dose is about 20 mg to 35 mg for about 12 weeks. Doses of DP-178, DP-107 or a pharmaceutically acceptable derivative should be administered in intervals of from about once per day to 4 times per day and preferably from about once every two days to once per day. A preferred dose is administered 20 to achieve peak plasma concentrations of DP-178, DP-107 or a pharmaceutically acceptable derivative thereof from about 1 mg/ml to 10 mg/ml. This may be achieved by the sterile injection of a 2.0% solution of the administered ingredients in buffered saline (any suitable saline solutions known to 25 those skilled in the art of chemistry may be used). Desirable blood levels may be maintained by a continuous infusion of DP-178 or DP-107 as ascertained by plasma levels measured by HPLC.

Effective amounts of the therapeutic agents, e.g., 30 antivirals to be used in combination with DP-178, DP-107 or a pharmaceutically acceptable derivative thereof are based on the recommended doses known to those skilled in the art for the various antivirals. For example, doses for AZT, ddI and interferon-Beta can be found in standard physician reference 35 texts. In addition, doses for other therapeutic agents, including antivirals, are reported in the literature, for example, ABT-538 is administered orally 600-1,200 mg/day on

day 1 and daily thereafter (Ho, et al., 1995, *Nature* 373: 123-126). These recommended or known levels will preferably be lowered by 10% to 50% of the cited dosage after testing the effectiveness of these dosages in combination with DP-5 178, DP-107 or a pharmaceutically acceptable derivative, using the assays described in Section 5.4 infra. It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust therapy to lower dosage due to toxicity, bone marrow, liver or kidney 10 dysfunctions or adverse drug-drug interaction. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response is not adequate (precluding toxicity).

A therapeutically effective dose refers to that amount 15 of the compound sufficient to result in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the 20 LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit large 25 therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little 30 or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be 35 formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration of the test compound which achieves a half-

maximal inhibition of RT production from infected cells compared to untreated control as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, 5 for example, by high performance liquid chromatography (HPLC).

**5.4. Pharmaceutical Formulations  
And Routes Of Administration**

10 Pharmaceutical compositions containing DP-178, DP-107 or a pharmaceutically acceptable derivative can be administered to a human patient, by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s) at doses to treat a viral infection, in 15 particular HIV infection. Techniques for formulation and administration of the compounds of the instant application may be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, PA, latest edition.

As demonstrated in the Example presented below in 20 Section 6, the antiviral activity of the peptides of the invention may show a pronounced type and subtype specificity, i.e., specific peptides may be effective in inhibiting the activity of only specific viruses. This feature of the invention presents many advantages. One such advantage, for 25 example, lies in the field of diagnostics, wherein one can use the antiviral specificity of the peptide of the invention to ascertain the identity of a viral isolate. With respect to HIV, one may easily determine whether a viral isolate consists of an HIV-1 or HIV-2 strain. For example, 30 uninfected CD-4<sup>+</sup> cells may be co-infected with an isolate which has been identified as containing HIV the DP-178 (SEQ ID:1) peptide, after which the retroviral activity of cell supernatants may be assayed, using, for example, the techniques described above in Section 5.2. Those isolates 35 whose retroviral activity is completely or nearly completely inhibited contain HIV-1. Those isolates whose viral activity is unchanged or only reduced by a small amount, may be

considered to not contain HIV-1. Such an isolate may then be treated with one or more of the other DP-178 peptides of the invention, and subsequently be tested for its viral activity in order to determine the identify of the viral isolate.

- 5 Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions 10 of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
- 15 Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Suitable routes of administration may, for example, 20 include oral, rectal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections; 25 transdermal, topical, vaginal and the like. Dosage forms include but are not limited to tablets, troches, dispersions, suspensions, suppositories, solutions, capsules, creams, patches, minipumps and the like.

Pharmaceutical compositions for use in accordance with 30 the present invention thus may be formulated in conventional manner using one or more physiologically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically. Proper formulation is 35 dependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueous solutions, preferably in

physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such 5 penetrants are generally known in the art.

For oral administration, the compounds can be formulated readily by combining the active compounds with pharmaceutically acceptable carriers well known in the art. Such carriers enable the compounds of the invention to be 10 formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated. Pharmaceutical preparations for oral use can be obtained solid excipient, optionally grinding a resulting mixture, and processing the 15 mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat 20 starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or 25 a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or 30 titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

35 Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as

glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft 5 capsules, the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.

10 For buccal administration, the compositions may take the form of tablets or lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to the present invention are conveniently delivered 15 in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit 20 may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g. gelatin for use in an inhaler or insufflator may be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.

25 The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The 30 compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral 35 administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily

injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain 5 substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated 10 solutions.

Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The compounds may also be formulated in rectal 15 compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds may also be formulated as a depot preparation.

20 Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an 25 acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.

A pharmaceutical carrier for the hydrophobic compounds of the invention is a cosolvent system comprising benzyl 30 alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase. The cosolvent system may be the VPD co-solvent system. VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in 35 absolute ethanol. The VPD co-solvent system (VPD:5W) consists of VPD diluted 1:1 with a 5% dextrose in water solution. This co-solvent system dissolves hydrophobic

compounds well, and itself produces low toxicity upon systemic administration. Naturally, the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics. Furthermore, 5 the identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and 10 other sugars or polysaccharides may substitute for dextrose.

The pharmaceutical compositions also may comprise suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, 15 starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols. Pharmaceutical compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the 20 effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

#### 5.5. Assays For Antiviral Activity

25 The antiviral activity exhibited by the combination therapy of the invention may be measured, for example, by easily performed in vitro assays, such as those described below, which can test the peptides' ability to inhibit syncytia formation, or their ability to inhibit infection by 30 cell-free virus. Using these assays, such parameters as the relative antiviral activity of the peptides, exhibit against a given strain of virus and/or the strain specific inhibitory activity of the peptide can be determined. A cell fusion assay may be utilized to test the peptides' ability to 35 inhibit HIV-induced syncytia formation in vitro. Such an assay may comprise culturing uninfected CD-4<sup>+</sup> cells (such as Molt or CEM cells, for example) in the presence of

chronically HIV-infected cells and a therapeutic agent to be assayed. For each combinational therapy, a range of concentrations may be tested. This range should include a control culture wherein no peptide has been added. Standard 5 conditions for culturing, well known to those of ordinary skill in the art, are used. After incubation for an appropriate period (24 hours at 37°C, for example) the culture is examined microscopically for the presence of multinucleated giant cells, which are indicative of cell 10 fusion and syncytia formation.

A reverse transcriptase (RT) assay may be utilized to test the peptides' ability to inhibit infection of CD-4<sup>+</sup> cells by cell-free HIV in combination with another antiviral agent. Such an assay may comprise culturing an appropriate 15 concentration (*i.e.*, TCID<sub>50</sub>) of virus and CD-4<sup>+</sup> cells in the presence of the peptide and the antiviral in combination to be tested. Culture conditions well known to those in the art are used. As above, a range of peptide concentrations may be used, in addition to a control culture wherein no peptide has 20 been added. After incubation for an appropriate period (*e.g.*, 7 days) of culturing, a cell-free supernatant is prepared, using standard procedures, and tested for the present of RT activity as a measure of successful infection. The RT activity may be tested using standard techniques such 25 as those described by, for example, Goff *et al.* (Goff, S. *et al.*, 1981, *J. Virol.* 38:239-248) and/or Willey *et al.* (Willey, R. *et al.*, 1988, *J. Virol.* 62:139-147). These references are incorporated herein by reference in their entirety.

30 Standard methods which are well-known to those of skill in the art may be utilized for assaying non-retroviral activity. See, for example, Pringle *et al.* (Pringle, C.R. *et al.*, 1985, *J. Medical Virology* 17:377-386) for a discussion of respiratory syncytial virus and parainfluenza virus 35 activity assay techniques. Further, see, for example, "Zinsser Microbiology", 1988, Joklik, W.K. *et al.*, eds., Appleton & Lange, Norwalk, CT, 19th ed., for a general review

of such techniques. These references are incorporated by reference herein in its entirety.

5            **5.5.1.    Testing Of Antiviral Compounds Active At Different Stages Of HIV-1 Infection**

Three separate in vitro assays for the study of antiviral compounds active at different stages of HIV infection (acute, co-cultivation, and chronic) are well known to those skilled in the art (Lambert et al., 1993, Antiviral Res. 21: 327-342). These assays can be used to assess the effects of DP-178, DP-107 or a pharmaceutically acceptable derivative thereof in combination with one of the described antiviral agents. All assays are carried out in triplicate in 24-well plates (Nunc.) 5-fold serial dilutions of inhibitor are made in 100% DMSO to yield 200 x final concentrations. Addition of 1/200 vol. of dilutions to culture wells resulted in a final concentration of 0.5% DMSO and the desired concentration of the inhibitor. Experiments are carried out either with dilutions of fixed ratio of the two inhibitors (i.e., 1:10 or 1:40, AZT:DP-178) or where the concentrations are varied.

First the acute infection assay models the rapid replication and cytopathic effects contributing to the loss of CD-4+ cells in vivo. Assay the treatment of acutely infected Molt4 cells to show the antiviral compounds are effective at inhibiting the spread of HIV-1 infection in T cells. For these assays,  $3 \times 10^4$  uninfected Molt4 cells per well are infected with 50 TCIDs of HIV-1 (strain LA1). Stocks of inhibitors are prepared in 100% DMSO, and added on day 0, immediately after the 1.5 hour virus absorption period. Cultures are re-fed on days 1 and 4 with medium containing the same concentration of inhibitor. Samples are harvested on day 7.

Second, chronically infected cells, containing integrated provirus and exhibiting moderate to low levels of continuous virus expression, are likely to represent in vivo reservoirs of infectious virions, which ultimately contribute

to disease progression. Chronically infected cells are washed three times in growth medium and plated at density  $6 \times 10^4$  cells per well. Inhibitors are added on day 0. Cultures are re-fed on days 1 and 3 with growth medium containing the 5 same concentration of inhibitor. Assays are harvested on day 5.

Third, the co-cultivation assay used in these studies is a relevant model of in vivo infection since it involves cell to cell fusion and spread as well as cell free spread of HIV-10 1 within the culture. For this assay,  $3 \times 10^4$  uninfected Molt4 cells are cocultivated with  $3 \times 10^3$  H9/LA1 or CEM/LA1 chronically infected cells per well in 24 well plates. Inhibitors are added on day 0, and the assay plates are re-fed on days 1 and 3 with growth medium containing the 15 inhibitors. The assay is harvested on day 5. Antiviral activity is measured by several parameters: Western blot analysis of pelleted cells from treated cultures, RT levels, and p24 antigen levels in the supernatant.

The combined drug effects are calculated by the multiple 20 drug analysis method of Chou and Talalay (Chou and Talalay, 1984, Adv. Enzyme Regul. 22:27-55) and 'Dose-Effect Analysis with Microcomputers' software (Chou and Chou, 1987, software and manual. p19-64. Elsevier Biosoft, Cambridge, UK) using the equation:

25

$$CI = \frac{(D)_1}{(Dx)_1} + \frac{(D)_2}{(Dx)_2} + \frac{\alpha(D)_1}{(Dx)_1} \frac{(D)_2}{(Dx)_2}$$

where CI is the combination index,  $(Dx)_i$  is the dose of 30 drug 1 required to produce x percent effect alone,  $(D)_i$  is the dose of drug 1 required to produce the same x percent effect in combination with  $(D)_2$ . The values of  $(Dx)_2$  and  $(D)_2$  are similarly derived from drug 2. The value of  $\alpha$  is determined from the plot of the dose effect curve using the median 35 effect equation:

$$fa/fu = (D/Dm)^m$$

where  $fa$  is the fraction affected by dose  $D$ ,  $fu$  is the uninfected fraction,  $D_m$  is the dose required for 50% effect and  $m$  is the slope of the dose-effect curve. For mutually exclusive drugs (i.e. similar modes of action), both drugs 5 alone and their parallel lines in the median effect plot. Mutually nonexclusive drugs (i.e. independent mode of action) will give parallel lines in the median effect plot, but in mixture will give a concave upward curve. If the agents are mutually exclusive  $\alpha$  is 0, and if they are mutually 10 nonexclusive,  $\alpha$  is 1. Values obtained assuming mutual nonexclusiveness will always be slightly greater than mutually exclusive drugs. CI values of  $<1$  indicate synergy, values  $>1$  indicate antagonism and values equal to 1 indicate additive effects.

15 The combined drug effects are also calculated by the MacSynergy computer program (Pritchard and Shipman, 1990, *Antiviral Research* 14: 181-206). This computer program allows three-dimensional graphic analysis of drug-drug interactions. The amount of synergy observed with 20 combinations of antiviral compounds is calculated by the MacSynergy program and is represented by a three-dimensional bar graph in which the percentage of drug interaction is plotted versus drug concentrations. The amount of synergy is represented by the heights of bars in the graph and 25 antagonism is plotted as a negative value below the floor of the graph.

6. EXAMPLE: DP-178 (SEQ ID:1) IS A POTENT INHIBITOR OF HIV-1 INFECTION

30 In this example, DP-178 (SEQ ID:1) is shown to be a potent inhibitor of HIV-1 mediated CD-4<sup>+</sup> cell-cell fusion and infection by cell free virus. In the fusion assay, this peptide completely blocks virus induced syncytia formation at concentrations of from 1-10 ng/ml. In the infectivity assay 35 the inhibitory concentration is somewhat higher, blocking infection at 90ng/ml. It is further shown that DP-178 (SEQ ID:1) shows that the antiviral activity of DP-178 (SEQ ID:1)

is highly specific for HIV-1. Additionally, a synthetic peptide, DP-185 (SEQ ID:3), representing a HIV-1-derived DP-178 homolog is also found to block HIV-1-mediated syncytia formation.

5

#### 6.1. Materials And Methods

##### 6.1.1. Peptide Synthesis

Peptides were synthesized using Fast Moc chemistry on an Applied Biosystems Model 431A peptide synthesizer. Amidated peptides were prepared using Rink resin (Advanced Chemtech) while peptides containing free carboxy termini were synthesized on Wang (p-alkoxy-benzyl-alcohol) resin (Bachem). First residues were double coupled to the appropriate resin and subsequent residues were single coupled. Each coupling step was followed by acetic anhydride capping. Peptides were cleaved from the resin by treatment with trifluoracetic acid (TFA) (10ml), H<sub>2</sub>O (0.5ml), thioanisole (0.5ml), ethanedithiol (0.25ml), and crystalline phenol (0.75g). Purification was carried out by reverse-phase HPLC. Approximately 50mg samples of crude peptide were chromatographed on a Waters Delta Pak C18 column (19mm x 30cm, 15 $\mu$  spherical) with a linear gradient; H<sub>2</sub>O/acetonitrile 0.1% TFA. Lyophilized peptides were stored desiccated and peptide solutions were made in water at about 1mg/ml. Electrospray mass spectrometry yielded the following results: DP-178 (SEQ ID:1):4491.87 (calculated 4491.94); DP-180 (SEQ ID:2):4491.45 (calculated 4491.94); DP-185 (SEQ ID:3):not done (calculated 4546.97).

30

##### 6.1.2. Virus

The HIV-1<sub>LA1</sub> virus was obtained from R. Gallo (Popovic, M. et al., 1984, *Science* 224:497-508) and propagated in CEM cells cultured in RPMI 1640 containing 10% fetal calf serum. Supernatant from the infected CEM cells was passed through a 0.2 $\mu$ m filter and the infectious titer estimated in a microinfectivity assay using the AA5 cell line to support virus replication. For this purpose, 25 $\mu$ l of serial diluted

virus was added to  $75\mu\text{l}$  AA5 cells at a concentration of  $2 \times 10^5/\text{ml}$  in a 96-well microtitre plate. Each virus dilution was tested in triplicate. Cells were cultured for eight days by addition of fresh medium every other day. On day 8 post 5 infection, supernatant samples were tested for virus replication as evidenced by reverse transcriptase activity released to the supernatant. The TCID<sub>50</sub> was calculated according to the Reed and Muench formula (Reed, L.J. et al., 1938, Am. J. Hyg. 27:493-497). The titer of the HIV-1<sub>LA1</sub> and 10 HIV-1<sub>MN</sub> stocks used for these studies, as measured on the AA5 cell line, was approximately  $1.4 \times 10^6$  and  $3.8 \times 10^4$  TCID<sub>50</sub>/ml, respectively.

#### 6.1.3. Cell Fusion Assay

15 Approximately  $7 \times 10^4$  Molt cells were incubated with  $1 \times 10^4$  CEM cells chronically infected with the HIV-1<sub>LA1</sub> virus in 96-well plates (one-half area cluster plates; Costar, Cambridge, MA) in a final volume of  $100\mu\text{l}$  culture medium as previously described (Matthews, T.J. et al., 1987, Proc. 20 Natl. Acad. Sci. USA 84: 5424-5428). Peptide inhibitors were added in a volume of  $10\mu\text{l}$  and the cell mixtures were incubated for 24 hr. at  $37^\circ\text{C}$ . At that time, multinucleated giant cells were estimated by microscopic examination at a 40x magnification which allowed visualization of the entire 25 well in a single field.

#### 6.1.4. Cell Free Virus Infection Assay

Synthetic peptides were incubated at  $37^\circ\text{C}$  with either 247 TCID<sub>50</sub> (for experiment depicted in FIG. 2), or 62 TCID<sub>50</sub> 30 (for experiment depicted in FIG.3) units of HIV-1<sub>LA1</sub> virus or 25 TCID<sub>50</sub> units of HIV-2<sub>NH2</sub> and CEM CD4<sup>+</sup> cells at peptide concentrations of 0, 0.04, 0.4, 4.0, and  $40\mu\text{g}/\text{ml}$  for 7 days. The resulting reverse transcriptase (RT) activity in counts per minute was determined using the assay described, below, 35 in Section 6.1.5. See, Reed, L.J. et al., 1938, Am. J. Hyg. 27: 493-497 for an explanation of TCID<sub>50</sub> calculations.

#### 6.1.5. Reverse Transcriptase Assay

The micro-reverse transcriptase (RT) assay was adapted from Goff *et al.* (Goff, S. *et al.*, 1981, *J. Virol.* 38:239-248) and Willey *et al.* (Willey, R. *et al.*, 1988, *J. Virol.* 52:139-147). Supernatants from virus/cell cultures are adjusted to 1% Triton-X100. A 10 $\mu$ l sample of supernatant was added to 50 $\mu$ l of RT cocktail in a 96-well U-bottom microtitre plate and the samples incubated at 37°C for 90 min. The RT cocktail contained 75mM KCl, 2mM dithiothreitol, 5mM MgCl<sub>2</sub>, 10 5 $\mu$ g/ml poly A (Pharmacia, cat. No. 27-4110-01), 0.25 units/ml oligo dT (Pharmacia, cat. No. 27-7858-01), 0.05% NP40, 50mM Tris-HCl, pH 7.8, 0.5 $\mu$ M non-radioactive dTTP, and 10 $\mu$ Ci/ml <sup>32</sup>P-dTTP (Amersham, cat. No. PB.10167).

After the incubation period, 40 $\mu$ l of reaction mixture 15 was applied to a Schleicher and Schuell (S+S) NA45 membrane (or DE81 paper) saturated in 2 x SSC buffer (0.3M NaCl and 0.003M sodium citrate) held in a S+S Minifold over one sheet of GB003 (S+S) filter paper, with partial vacuum applied. Each well of the minifold was washed four times with 200 $\mu$ l 20 2xSSC, under full vacuum. The membrane was removed from the minifold and washed 2 more times in a pyrex dish with an excess of 2xSSC. Finally, the membrane was drained on absorbent paper, placed on Whatman #3 paper, covered with Saran wrap, and exposed to film overnight at -70°C.

25

#### 6.2. Results

##### 6.2.1. Peptide Inhibition Of Infected Cell-Induced Syncytia Formation

The initial screen for antiviral activity assayed 30 peptides' ability to block syncytium formation induced by overnight co-cultivation of uninfected Molt4 cells with chronically HIV-1 infected CEM cells. The results of several such experiments are presented herein. In the first of these experiments, serial DP-178 (SEQ ID:1) peptide concentrations between 10 $\mu$ g/ml and 12.5ng/ml were tested for blockade of the 35 cell fusion process. For these experiments, CEM cells chronically infected with either HIV-1<sub>LA1</sub>, HIV-1<sub>MN</sub>, HIV-1<sub>RF</sub>, or

HIV-1<sub>SP</sub> virus were cocultivated overnight with uninfected Molt 4 cells. The results (FIG. 4) show that DP-178 (SEQ ID:1) afforded complete protection against each of the HIV-1 isolates down to the lowest concentration of DP-178 (SEQ ID:1) used. For HIV<sub>LA</sub> inhibition, the lowest concentration tested was 12.5ng/ml; for all other HIV-1 viruses, the lowest concentration of DP-178 (SEQ ID:1) used in this study was 100ng/ml. A second peptide, DP-180 (SEQ ID:2), containing the same amino acid residues as DP-178 (SEQ ID:1) but 10 arranged in a random order exhibited no evidence of anti-fusogenic activity even at the high concentration of 40 $\mu$ g/ml (FIG. 4). These observations indicate that the inhibitory effect of DP-178 (SEQ ID:1) is primary sequence-specific and not related to non-specific peptide/protein interactions. 15 The actual endpoint (i.e., the lowest effective inhibitory concentration) of DP-178 inhibitory action is within the range of 1-10 ng/ml.

The next series of experiments involved the preparation and testing of a DP-178 (SEQ ID:1) homolog for its ability to 20 inhibit HIV-1-induced syncytia formation. As shown in FIG. 1, the sequence of DP-185 (SEQ ID:3) is slightly different from DP-178 (SEQ ID:1) in that its primary sequence is taken from the HIV-1<sub>SP</sub> isolate and contains several amino acid differences relative to DP-178 (SEQ ID:1) near the N 25 terminus. As shown in FIG. 4, DP-185 (SEQ ID:3), exhibits inhibitory activity even at 312.5ng/ml, the lowest concentration tested.

The next series of experiments involved a comparison of DP-178 (SEQ ID:1) HIV-1 and HIV-2 inhibitory activity. As 30 shown in FIG. 5, DP-178 (SEQ ID:1) blocked HIV-1-mediated syncytia formation at peptide concentrations below 1ng/ml. DP-178 (SEQ ID:1) failed, however, to block HIV-2 mediated syncytia formation at concentrations as high as 10 $\mu$ g/ml. This striking 4 log selectivity of DP-178 (SEQ ID:1) as an 35 inhibitor of HIV-1-mediated cell fusion demonstrates an unexpected HIV-1 specificity in the action of DP-178 (SEQ ID:1). DP-178 (SEQ ID:1) inhibition of HIV-1-mediated cell

fusion, but the peptide's inability to inhibit HIV-2 mediated cell fusion in the same cell type at the concentrations tested provides further evidence for the high degree of selectivity associated with the antiviral action of 5 DP-178 (SEQ ID:1).

#### **6.2.2. Peptide Inhibition Of Infection By Cell-Free Virus**

DP-178 (SEQ ID:1) was next tested for its ability to 10 block CD-4<sup>+</sup> CEM cell infection by cell free HIV-1 virus. The results, shown in FIG. 2, are from an experiment in which DP-178 (SEQ ID:1) was assayed for its ability to block infection of CEM cells by an HIV-1<sub>LAI</sub> isolate. Included in the experiment were three control peptides, DP-116 (SEQ ID:9), 15 DP-125 (SEQ ID:8), and DP-118 (SEQ ID:10). DP-116 (SEQ ID:9) represents a peptide previously shown to be inactive using this assay, and DP-125 (SEQ ID:8; Wild, C. *et al.*, 1992, Proc. Natl. Acad. Sci. USA 89:10,537) and DP-118 (SEQ ID:10) are peptides which have previously been shown to be active in 20 this assay. Each concentration (0, 0.04, 0.4, 4, and 40 $\mu$ g/ml) of peptide was incubated with 247 TCID<sub>50</sub> units of HIV-1<sub>LAI</sub> virus and CEM cells. After 7 days of culture, cell-free supernatant was tested for the presence of RT activity as a measure of successful infection. The results, shown in 25 FIG. 2, demonstrate that DP-178 (SEQ ID:1) inhibited the de novo infection process mediated by the HIV-1 viral isolate at concentrations as low as 90ng/ml (IC50=90ng/ml). In contrast, the two positive control peptides, DP-125 (SEQ: ID:8) and DP-118 (SEQ ID:10), had over 60-fold higher IC50 30 concentrations of approximately 5 $\mu$ g/ml.

In a separate experiment, the HIV-1 and HIV-2 inhibitory action of DP-178 (SEQ ID:1) was tested with CEM cells and either HIV-1<sub>LAI</sub> or HIV-2<sub>NH2Z</sub>. 62 TCID<sub>50</sub> HIV-1<sub>LAI</sub> or 25 GCID<sub>50</sub> HIV-2<sub>NH2Z</sub> were used in these experiments, and were incubated for 7 35 days. As may be seen in FIG. 3, DP-178 (SEQ ID:1) inhibited HIV-1 infection with an IC50 of about 31ng/ml. In contrast, DP-178 (SEQ ID:1) exhibited a much higher IC50 for HIV-2<sub>NH2Z</sub>,

thus making DP-178 (SEQ ID:1) two logs more potent as a HIV-1 inhibitor than a HIV-2 inhibitor. This finding is consistent with the results of the fusion inhibition assays described, above, in Section 6.2.1, and further supports a significant 5 level of selectivity (i.e., for HIV-1 over HIV-2).

7. EXAMPLE: THE HIV-1 INHIBITOR, DP-178 (SEQ ID:1) IS NON-CYTOTOXIC

In this Example, the 36 amino acid synthetic peptide 10 inhibitor DP-178 (SEQ ID:1) is shown to be non-cytotoxic to cells in culture, even at the highest peptide concentrations (40 $\mu$ g/ml) tested.

7.1. Materials And Methods

15 Cell proliferation and toxicity assay: Approximately 3.8x10<sup>5</sup> CEM cells for each peptide concentration were incubated for 3 days at 37°C in T25 flasks. Peptides tested were DP-178 (SEQ ID:1) and DP-116 (SEQ ID:9), as described in FIG. 1. The concentrations of each peptide used were 0, 2.5, 20 10, and 40 $\mu$ g/ml. Cell counts were taken at incubation times of 0, 24, 48, and 72 hours.

7.2. Results

Whether the potent HIV-1 inhibitor DP-178 (SEQ ID:1) 25 exhibited any cytotoxic effects was assessed by assaying the peptide's effects on the proliferation and viability of cells in culture. CEM cells were incubated in the presence of varying concentrations of DP-178 (SEQ ID:1), and DP-116 (SEQ ID:9), a peptide previously shown to be ineffective as a HIV 30 inhibitor (Wild, C. et al., 1992, Proc. Natl. Acad. Sci. USA 89:10,537-10,541). Additionally, cells were incubated in the absence of either peptide.

The results of the cytotoxicity study demonstrate that DP- 178 (SEQ ID:1) exhibits no cytotoxic effects on cells in 35 culture. As can be seen, below, in Table V, even the proliferation and viability characteristics of cells cultured for 3 days in the presence of the highest concentration of

DP-178 (SEQ ID:1) tested (40 $\mu$ g/ml) do not significantly differ from the DP-116 (SEQ ID:9) or the no-peptide controls. The cell proliferation data is also represented in graphic form in FIG. 6. As was demonstrated in the Working Example 5 presented above in Section 6, DP-178 (SEQ ID:1) completely inhibits HIV-1 mediated syncytia formation at peptide concentrations between 1 and 10ng/ml, and completely inhibits cell-free viral infection at concentrations of at least 90ng/ml. Thus, this study demonstrates that even at peptide 10 concentrations greater than 3 log higher than the HIV inhibitory dose, DP-178 (SEQ ID:1) exhibits no cytotoxic effects.

15

20

25

30

35

TABLE V

		% Viability at time (hours)				
5	Peptide	Concentration $\mu$ g/ml	0	24	48	72
10	DP178 (SEQ ID:1)	40	98	97	95	97
		10	98	97	98	98
		2.5	98	93	96	96
15	DP116 (SEQ ID:9)	40	98	95	98	97
		10	98	95	93	98
		2.5	98	96	98	99
20	No	0	98	97	99	98
	Peptide					

8. EXAMPLE: ANTI-VIRAL ACTIVITY OF DP-107 AND DP-178  
PEPTIDE TRUNCATIONS AND MUTATIONS

30 The Example presented in this Section represents a study of the antiviral activity of DP107 and DP178 truncations and mutations. It is demonstrated that several of these DP107 and DP178 modified peptides exhibit substantial antiviral activity.

### 8.1. Materials And Methods

Anti-HIV assays: The antiviral assays performed were as those described, above, in Section 6.1. Assays utilized HIV-1/IIIB and/or HIV-2 NIHZ isolates. Purified peptides were 5 used, unless otherwise noted in FIGS. 5A-C.

Peptides: The peptides characterized in the study presented herein were:

1) FIGS. 5A-C present peptides derived from the region around and containing the DP178 region of the HIV-1 10 BRU isolate. Specifically, this region spanned from gp41 amino acid residue 615 to amino acid residue 717. The peptides listed contain truncations of this region and/or mutations which vary from the DP178 sequence amino acid sequence. 15 Further, certain of the peptides have had amino- and/or carboxy-terminal groups either added or removed, as indicated in the figures; and 20 2) FIG. 6. presents peptides which represent truncations of DP107 and/or the gp41 region surrounding the DP107 amino acid sequence of HIV-1 BRU isolate. Certain of the peptides are unblocked or biotinylated, as indicated in the figure.

Blocked peptides contained an acyl N-terminus and an amido C-terminus.

25

### 8.2. Results

Anti-HIV antiviral data was obtained with the group 1 DP178-derived peptides listed in FIG. 5A-C. The full-length, non-mutant DP178 peptide (referred to in FIG. 5A-C as T20) 30 results shown are for 4ng/ml.

In FIG. 5, a number of the DP178 truncations exhibited a high level of antiviral activity, as evidenced by their low IC<sub>50</sub> values. These include, for example, test peptides T-50, T-624, T-636 to T-641, T-645 to T-650, T-652 to T-654 and T-35 656. T-50 represents a test peptide which contains a point mutation, as indicated by the residue's shaded background. The HIV-1-derived test peptides exhibited a distinct strain-

specific antiviral activity, in that none of the peptides tested on the HIV-2 NIHZ isolate demonstrated appreciable anti-HIV-2 antiviral activity.

Among the peptides listed in FIG. 5B, are test peptides 5 representing the amino (T-4) and carboxy (T-3) terminal halves of DP178 were tested. The amino terminal peptide was not active ( $IC_{50}>400\mu\text{g}/\text{ml}$ ) whereas the carboxy terminal peptide showed potent antiviral activity ( $IC_{50}= 3\mu\text{g}/\text{ml}$ ). A number of additional test peptides also exhibited a high 10 level of antiviral activity. These included, for example, T-61/T-102, T-217 to T-221, T-235, T-381, T-677, T-377, T-590, T-378, T-591, T-271 to T-272, T-611, T-222 to T-223 and T-60/T-224. Certain of the antiviral peptides contain point 15 mutations and/or amino acid residue additions which vary from the DP178 amino acid sequence.

In FIG. 5C, point mutations and/or amino and/or carboxy-terminal modifications are introduced into the DP178 amino acid sequence itself. As shown in the figure, the majority of the test peptides listed exhibit potent antiviral 20 activity.

Truncations of the DP107 peptide (referred to in FIG. 5 as T21) were also produced and tested, as shown in FIG. 6. FIG. 6 also presents data concerning blocked and unblocked peptides which contain additional amino acid residues from 25 the gp41 region in which the DP107 sequence resides. Most of these peptides showed antiviral activity, as evidenced by their low  $IC_{50}$  values.

Thus, the results presented in this Section demonstrate that not only do the full length DP-107 and DP-178 peptides 30 exhibit potent antiviral activity, but truncations of these peptides also possess substantial antiviral character.

**9. EXAMPLE: POTENTIAL SIV DP178/DP107 ANALOGS:  
ANTIVIRAL CHARACTERIZATION**

35 In the Example presented herein, simian immunodeficiency virus (SIV) DP178-like peptides identified by utilizing the computer-assisted search motifs described above, were tested

for anti-SIV activity. It is demonstrated that several of the identified peptides exhibit potent antiviral capability.

#### 9.1. MATERIALS AND METHODS

5 Anti-SIV antiviral assays: The assay utilized herein were as reported in Langolis et al. (Langolis, A.J. et al., 1991, AIDS Research and Human Retroviruses 7:713-720).

Peptides: The peptides characterized in the study presented herein were peptides T-391 to T-400, as shown in 10 FIG. 7. These peptides represent a walk through the DP178-like region of the SIV TM protein.

Each peptide was tested at 2-fold serial dilutions ranging from 100 $\mu$ g/ml to approximately 100ng/ml. For each of the assays, a well containing no peptide was also used.

15

#### 9.2. RESULTS

The data summarized in FIG. 7 represents antiviral information obtained via "peptide walks" through the DP178-like region of the SIV TM protein.

20 As shown in FIG. 7, peptides T-391 to T-400 were tested and exhibited a potent antiviral activity as crude peptides.

Thus, the computer assisted searches described, hereinabove, as in for example, the Example presented in Section 8, for example, successfully identified viral peptide 25 domains that represent highly promising anti-SIV antiviral compounds.

The present invention is not to be limited in scope by the specific embodiments described which are intended as single illustrations of individual aspects of the invention, 30 and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such 35 modifications are intended to fall within the scope of the appended claims.

What is claimed is:

1. A method of treating HIV infection in a subject which comprises administering an effective amount of DP-107 5 or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

2. A method of treating HIV infection in a subject which comprises administering an effective amount of DP-178 10 or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

3. The method of claims 1 or 2 wherein said therapeutic agent is an antiviral.

15

4. The method of claim 3 wherein said anti-HIV agent is a reverse transcriptase inhibitor, a viral protease inhibitor, a cytokine, a cytokine inhibitor, a glycosylation inhibitor or a viral mRNA processing inhibitor.

20

5. The method of claim 3 wherein said antiviral is a nucleoside analogue.

6. The method of claim 5 wherein said nucleoside 25 analogue is AZT, dDI, dDC, dDA, d4T or 3TC.

7. The method of claim 3 wherein said antiviral is interferon- $\alpha$ , interferon- $\beta$  or interferon- $\gamma$ .

30

8. The method of claim 2 wherein said DP-178 derivative is a peptide of the group comprising T-624, T-636 to T-641, T-645 to T-650, T-652 to T-654, or T-656.

9. A method of inhibiting HIV replication comprising 35 administering to the subject an effective amount of DP-107 or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

10. A method of inhibiting HIV replication comprising administering to the subject an effective amount of DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

5

11. A method for the inhibition of transmission of an HIV retrovirus to a cell, comprising contacting the cell with an effective amount of DP-107 or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

12. A method for the inhibition of transmission of an HIV retrovirus to a cell, comprising contacting the cell with an effective amount of DP-178 or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

13. The method of claims 9, 10, 11 or 12 wherein said therapeutic agent is an antiviral.

20

14. The method of claim 13 wherein said antiviral agent is a reverse transcriptase inhibitor, a viral protease inhibitor, a cytokine, a cytokine inhibitor, a glycosylation inhibitor or a viral mRNA processing inhibitor.

25

15. The method of claim 13 wherein said antiviral is a nucleoside analog.

16. The method of claim 15 wherein said nucleoside  
30 analog is AZT, ddI, dDC, ddA, d4T or 3TC.

17. The method of claim 13 wherein said antiviral is interferon- $\alpha$ , interferon- $\beta$  or interferon- $\gamma$ .

35 18. The method of claim 1, 2, 9 or 10 wherein said administration is sequential.

19. The method of claim 1, 2, 9 or 10 wherein said administration is simultaneous.

20. The method of claim 1, 2, 9 or 10 wherein said administration is oral.

21. The method of claim 1, 2, 9 or 10 wherein said administration is parenteral.

10 22. The method of claim 21 wherein said administration is intravenous.

23. A pharmaceutically acceptable composition useful for the treatment of HIV infection which comprises an effective amount of DP-178 or a pharmaceutically acceptable derivative thereof, an effective amount another therapeutic agent and a pharmaceutically acceptable carrier.

24. A pharmaceutical composition useful for the treatment of HIV infection which comprises an effective amount of DP-107 or a pharmaceutically acceptable derivative thereof, an effective amount of another therapeutic agent and a pharmaceutically acceptable carrier.

25 25. The pharmaceutical composition of claim 23 or 24 wherein said therapeutic agent is an antiviral.

26. The pharmaceutical composition of claim 25 wherein said antiviral agent is a nucleoside analog.

30

27. The pharmaceutical composition of claim 26 wherein said nucleoside analog is AZT, dDI, ddC, ddA, or 3TC.

28. A method of treating HIV infection in a subject 35 which comprises (a) administering an effective amount of DP-107, DP-178 or a pharmaceutically acceptable derivative thereof; (b) administering an effective amount of another

antiviral; and (c) administering DP-107, DP-178 or a pharmaceutically acceptable derivative thereof.

29. The method of claim 28 wherein DP-107 or a  
5 pharmaceutically acceptable derivative thereof, an effective amount of another therapeutic agent and a pharmaceutically acceptable carrier is administered in step (a) and DP-178 or a pharmaceutically acceptable derivative thereof is administered in step (c).

10

30. The method of claim 29 wherein step (a) to (c) are repeated until the symptoms of the disease are alleviated.

31. A method of treating HIV infection in a subject  
15 which comprises administering an effective amount of a DP-178-like peptide or a pharmaceutically acceptable derivative thereof and an effective amount of at least one therapeutic agent.

20 32. The method of claim 31 wherein the DP-178-like peptide is derived from the simian immunodeficiency virus.

33. The method of claim 32 wherein the DP-178-like peptide is chosen from the group comprising T-391, T-392, T-25 393, T-394, T-395, T-396, T-397, T-398, T-399, or T-400.

30

35

1/20

HIV1LAI (DP-178; SEQ ID:1)	YTSLIHSLIEESQQEQKNEQELLELDKwaslWWMF
HIV1SF2 (DP-185; SEQ ID:3)	YTNTIYMLLEESQQEQKNEQELLELDKwaslWWMF
HIV1RF (SEQ ID:4)	YTGIIYMLLEESQQEQKNEQELLELDKwaslWWMF
HIV1MN (SEQ ID:5)	YTSLIYSLEKSQTQQEQKNEQELLELDKwaslWWMF
HIV2R0D (SEQ ID:6)	LEANISKSLEQAQIQQEKNNMYELQKLNNSWDIFGNWF
HIV2N1HZ (SEQ ID:7)	LEANISQSLEQAQIQQEKNNMYELQKLNNSWDVFTNWL
DP180 (SEQ ID:2)	SSESFTLLEQWNMMKLQLAEQWLEQINKEHYLEDIS
DP118 (SEQ ID:10)	QQLLDWVKRQQEMRLTVWCTKNLQARVTAIEKYLKDQ
DP125 (SEQ ID:8)	CGGNNLRLRAIEAQQLLQLTVWGIKQLQARIIAVERYLKDQ
DP116 (SEQ ID:9)	LQARIIAVERYLKDQQQ

FIG. 1

2/20




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/20




FIG.3

SUBSTITUTE SHEET (RULE 26)

4/20




FIG. 4

SUBSTITUTE SHEET (RULE 26)

5/20

FIG. 5A(1)

**SUBSTITUTE SHEET (RULE 26)**

6/20

FIG.5A(II)

**SUBSTITUTE SHEET (RULE 26)**

7/20

FIG. 5A (111)

**SUBSTITUTE SHEET (RULE 26)**

8/20

\* CRUDE PREP RESULT

FIG. 5A (iv)

**SUBSTITUTE SHEET (RULE 26)**

9/20

FIG. 5B(1)

**SUBSTITUTE SHEET (RULE 26)**

10/20

FIG.5B(II)

		HIV-1/IIIB 1C50 (ng/ml)
	T4	>400000
	T228	>50000
	T700	>100000
	T715	ND
	T65/T716	ND
	T714	ND
	T712	ND
	T64	ND
	T63	ND
	T62	ND
	T3	3000
	T61/T102	64000
	T217	40000
	T218	25000
	T219	48000

SUBSTITUTE SHEET (RULE 26)

11/20

T220	X	LLELDKWAASLWNWF
T221	X	LELDKWAASLWNWF
T234	X	LELDKWAASLWNWF
T235	X	LELDKWAASLWNWF
T570	X	LELDKWEVKDLOKMR
T381	X	LELDKWAASLWNWF
T382	X	LELDKWAASLWNWF
T677	X	LELDKWAASLWNWF
T376	X	CLLEDKWAASLWNWF
T589	X	CLLEDKWAASLWNWF
T377	X	CLLEDKWAASLWNWF
T590	X	CLLEDKWAASLWNWF
T378	X	CLLEDKWAASLWNWF
T591	X	CLLEDKWAASLWNWF
T270	X	CLLEDKWAASLWNWF
T271	X	CLLEDKWAASLWNWF
T272	X	CLLEDKWAASLWNWF
T273	X	CLLEDKWAASLWNWF
T608	X	CLLEDKWAASLWNWF
T609	X	CLLEDKWAASLWNWF
T610	X	CLLEDKWAASLWNWF
T611	X	CLLEDKWAASLWNWF
T612	X	CLLEDKWAASLWNWF
T222	X	CLLDKWAASLWNWF
T223	X	CLLDKWAASLWNWF
T60/T224	X	CLLDKWAASLWNWF
T225	X	CLLDKWAASLWNWF
T226	X	CLLDKWAASLWNWF
T227	X	CLLDKWAASLWNWF

FIG. 5B(III)

12/20

FIG. 5B(IV)

**SUBSTITUTE SHEET (RULE 26)**

13/20

FIG. 5C(1)

**SUBSTITUTE SHEET (RULE 26)**

14/20

FIG. 5C (1)

**SUBSTITUTE SHEET (RULE 26)**

15/20

FIG. 5C ( )

**SUBSTITUTE SHEET (RULE 26)**

16/20

Q	L	D	K	W	A	S	L	W	N	W	F	T99	56
Q	L	D	K	W	A	S	L	W	N	W	F	T103	ND
Q	L	D	K	W	A	S	L	W	N	W	F	T112	3
Q	L	D	K	W	A	S	L	W	N	W	F	T113	25
Q	L	D	K	W	A	S	L	W	N	W	F	T114	19
Q	L	D	K	W	A	S	L	W	N	W	F	T115	23
Q	L	D	K	W	A	S	L	W	N	W	F	T116	1000
Q	L	D	K	W	A	S	L	W	N	W	F	T229	>100000
Q	L	D	K	W	A	S	L	W	N	W	F	T230	6
Q	L	D	K	W	A	S	L	W	N	W	F	T231	4
Q	L	D	K	W	A	S	L	W	N	W	F	T379	0.3
Q	L	D	K	W	A	S	L	W	N	W	F	T701	3
Q	L	D	K	W	A	S	L	W	N	W	F	T702	36
Q	L	D	K	W	A	S	L	W	N	W	F	T703	0.5
Q	L	D	K	W	A	S	L	W	N	W	F	T704	510
Q	L	D	K	W	A	S	P	W	N	W	F	T705	14
Q	L	D	K	W	A	S	L	W	N	S	F	T706	68
Q	L	D	K	W	A	S	L	H	K	S	A	T156	80000
Q	L	D	K	W	A	S	L	H	K	S	A	T89	>100000
Q	L	D	K	W	A	S	L	H	K	S	A	T90	>100000

FIG.5C(IV)

SUBSTITUTE SHEET (RULE 26)

17/20

**SUBSTITUTE SHEET (RULE 26)**

18/20

QARILAAVERYLKDQQLLG1WG		HIV/111B
		IC50(ug/ml)
	6	T10 50
	0	T37 75*
	2	T48 83*
		T36 45*
		T8 50
		T33 >100*
		T21 2
		T86 2
		T1 >100
		T2 ND
		T7 26
		A34 >100*
		T6 44
		T35 >100*
		T3 55

FIG. 6(II)

SUBSTITUTE SHEET (RULE 26)

19/20

SIMIAN IMMUNODEFICIENCY VIRUS MM251		DP178-LIKE		245		19/20	
RESIDUE	245	19	20	Q	W	W	Q
I- 390	245	T	W	Q	E	W	E
I- 391	246	W	Q	E	W	K	V
I- 392	247	Q	E	W	E	K	V
I- 393	248	E	W	E	K	V	D
I- 394	249	W	E	K	V	D	F
I- 395	250	E	R	K	V	D	F
I- 396	251	R	K	D	F	D	F
I- 397	252	K	V	D	F	D	F
I- 398	253	V	D	F	E	D	F
I- 399	254	D	F	E	N	D	F
I- 400	255	F	L	E	E	D	F

FIG. 7(1)

20/20

			ANTIVIRAL	ACTIVITY	SIV		
		RESIDUE	47			NT	
291				35	T390		
	280			35	T391	+++	
	281			35	T392	+++	
	282			35	T393	+++	
	283			35	T394	+++	
	284			35	T395	+++	
	285			35	T396	+++	
	286			35	T397	+++	
	287			35	T398	+++	
	288			35	T399	+++	
	289			35	T400	+++	
	290						

FIG.7(II)

SUBSTITUTE SHEET (RULE 26)

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US96/09499

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/00, 38/02; C07K 1/00, 5/00, 7/00, 17/00  
US CL : 514/12; 530/300, 324, 350

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/12; 530/300, 324, 350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  
APS, BIOSIS, CAS ONLINE, MEDLINE.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US, A, 5,141,867 (IVANOFF et al.) 25 August 1992, see entire document.	1-33
Y	US, A, 5,077,280 (SOMMADODSSI et al.) 31 December 1991, see entire document.	1-33
Y	US, A, 4,950,652 (CARTER) 21 August 1990, see entire document.	1-33

Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 AUGUST 1996

Date of mailing of the international search report

02 OCT 1996


Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Authorized officer

  
AVIS M. DAVENPORT

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196



1/20

HIV1LAI (DP-178; SEQ ID:1)	YTSLIHSLEESQQEQKNEQELLELDKMASLWKF
HIV1SF2 (DP-185; SEQ ID:3)	YTNTIYALLEESQQEQKNEQELLELDKMASLWKF
HIV1RF (SEQ ID:4)	YTGIIYALLEESQQEQKNEQELLELDKMASLWKF
HIV1IN (SEQ ID:5)	YTSLIYSLEKSFQEQKNEQELLELDKMASLWKF
HIV2R0D (SEQ ID:6)	LEANISKSLEQAQIQQEQKNEQELQKLNSKQDIFGKF
HIV2NIHZ (SEQ ID:7)	LEANISQSLEQAQIQQEQKNEQELQKLNSKQDFTMIL
DP180 (SEQ ID:2)	SSESFTYLEQWINKLQLAEQMLEQINERKYLEDIS
DP118 (SEQ ID:10)	QWLLDWKRCQEMRLTVWGTTKWQLQARYTAIEKYI KQQ
DP125 (SEQ ID:8)	CGGNNLIRATEAQDHLQLTVIGIKOLQARILAVERYLKQQ
DP116 (SEQ ID:9)	LQARILAVERYLKQQQ

FIG. 1

2/20




FIG. 2

SUBSTITUTE SHEET (RULE 26)

3/20




FIG.3

SUBSTITUTE SHEET (RULE 26)

4/20




FIG. 4

SUBSTITUTE SHEET (RULE 26)

5/20

FIG. 5A(1)

**SUBSTITUTE SHEET (RULE 26)**

6/20

		HIV-1/1110		HIV-2 NIH	
		IC50 ng/ml		IC50 ng/ml	
		T651	297*	T660	258*
W	W	1659	2290*	1659	2290*
W	W	1658	191*	1658	191*
W	W	1657	128*	1657	128*
W	W	1656	5*	1656	5*
W	W	1655	2300*	1655	2300*
W	W	1654	1*	1654	1*
W	W	1653	63*	1653	63*
W	W	1652	4*	1652	4*
W	W	1651	398*	1651	398*
W	W	1625	ND	1625	ND
W	W	1650	44*	1650	44*
W	W	1649	8*	1649	8*
W	W	1624	2	1624	2
W	W	150	6	150	6
W	W	1648	36	1648	36
W	W	1647	44	1647	44
W	W	1711	ND	1711	ND
W	W	1621	229	1621	229
W	W	1646	63	1646	63
W	W	1645	85	1645	85
W	W	1644	4460*	1644	4460*
W	W	1643	1690*	1643	1690*
W	W	1642	1450*	1642	1450*

FIG.5A(II)

SUBSTITUTE SHEET (RULE 26)

7/20

FIG. 5A

**SUBSTITUTE SHEET (RULE 26)**

8/20

		• OZONE PREP RESULT	
1622	210	120	0.5
1623	396	1641	98
1624	15	>10000	
1625	20	0.6	
1626	110		
1627	12	<1000	
1628	5	>10000	
1629	21	>10000	
1630	139		
1631	134	54	
1632	186		
1633	163		
1634	163		
1635	139		
1636	163		
1637	12	<1000	
1638	5	>10000	
1639	21	>10000	
1640	139		
1641	1641		
1642	1642		
1643	1643		
1644	1644		
1645	1645		
1646	1646		
1647	1647		
1648	1648		
1649	1649		
1650	1650		
1651	1651		
1652	1652		
1653	1653		
1654	1654		
1655	1655		
1656	1656		
1657	1657		
1658	1658		
1659	1659		
1660	1660		
1661	1661		
1662	1662		
1663	1663		
1664	1664		
1665	1665		
1666	1666		
1667	1667		
1668	1668		
1669	1669		
1670	1670		
1671	1671		
1672	1672		
1673	1673		
1674	1674		
1675	1675		
1676	1676		
1677	1677		
1678	1678		
1679	1679		
1680	1680		
1681	1681		
1682	1682		
1683	1683		
1684	1684		
1685	1685		
1686	1686		
1687	1687		
1688	1688		
1689	1689		
1690	1690		
1691	1691		
1692	1692		
1693	1693		
1694	1694		
1695	1695		
1696	1696		
1697	1697		
1698	1698		
1699	1699		
1700	1700		
1701	1701		
1702	1702		
1703	1703		
1704	1704		
1705	1705		
1706	1706		
1707	1707		
1708	1708		
1709	1709		
1710	1710		
1711	1711		
1712	1712		
1713	1713		
1714	1714		
1715	1715		
1716	1716		
1717	1717		
1718	1718		
1719	1719		
1720	1720		
1721	1721		
1722	1722		
1723	1723		
1724	1724		
1725	1725		
1726	1726		
1727	1727		
1728	1728		
1729	1729		
1730	1730		
1731	1731		
1732	1732		
1733	1733		
1734	1734		
1735	1735		
1736	1736		
1737	1737		
1738	1738		
1739	1739		
1740	1740		
1741	1741		
1742	1742		
1743	1743		
1744	1744		
1745	1745		
1746	1746		
1747	1747		
1748	1748		
1749	1749		
1750	1750		
1751	1751		
1752	1752		
1753	1753		
1754	1754		
1755	1755		
1756	1756		
1757	1757		
1758	1758		
1759	1759		
1760	1760		
1761	1761		
1762	1762		
1763	1763		
1764	1764		
1765	1765		
1766	1766		
1767	1767		
1768	1768		
1769	1769		
1770	1770		
1771	1771		
1772	1772		
1773	1773		
1774	1774		
1775	1775		
1776	1776		
1777	1777		
1778	1778		
1779	1779		
1780	1780		
1781	1781		
1782	1782		
1783	1783		
1784	1784		
1785	1785		
1786	1786		
1787	1787		
1788	1788		
1789	1789		
1790	1790		
1791	1791		
1792	1792		
1793	1793		
1794	1794		
1795	1795		
1796	1796		
1797	1797		
1798	1798		
1799	1799		
1800	1800		
1801	1801		
1802	1802		
1803	1803		
1804	1804		
1805	1805		
1806	1806		
1807	1807		
1808	1808		
1809	1809		
1810	1810		
1811	1811		
1812	1812		
1813	1813		
1814	1814		
1815	1815		
1816	1816		
1817	1817		
1818	1818		
1819	1819		
1820	1820		
1821	1821		
1822	1822		
1823	1823		
1824	1824		
1825	1825		
1826	1826		
1827	1827		
1828	1828		
1829	1829		
1830	1830		
1831	1831		
1832	1832		
1833	1833		
1834	1834		
1835	1835		
1836	1836		
1837	1837		
1838	1838		
1839	1839		
1840	1840		
1841	1841		
1842	1842		
1843	1843		
1844	1844		
1845	1845		
1846	1846		
1847	1847		
1848	1848		
1849	1849		
1850	1850		
1851	1851		
1852	1852		
1853	1853		
1854	1854		
1855	1855		
1856	1856		
1857	1857		
1858	1858		
1859	1859		
1860	1860		
1861	1861		
1862	1862		
1863	1863		
1864	1864		
1865	1865		
1866	1866		
1867	1867		
1868	1868		
1869	1869		
1870	1870		
1871	1871		
1872	1872		
1873	1873		
1874	1874		
1875	1875		
1876	1876		
1877	1877		
1878	1878		
1879	1879		
1880	1880		
1881	1881		
1882	1882		
1883	1883		
1884	1884		
1885	1885		
1886	1886		
1887	1887		
1888	1888		
1889	1889		
1890	1890		
1891	1891		
1892	1892		
1893	1893		
1894	1894		
1895	1895		
1896	1896		
1897	1897		
1898	1898		
1899	1899		
1900	1900		
1901	1901		
1902	1902		
1903	1903		
1904	1904		
1905	1905		
1906	1906		
1907	1907		
1908	1908		
1909	1909		
1910	1910		
1911	1911		
1912	1912		
1913	1913		
1914	1914		
1915	1915		
1916	1916		
1917	1917		
1918	1918		
1919	1919		
1920	1920		
1921	1921		
1922	1922		
1923	1923		
1924	1924		
1925	1925		
1926	1926		
1927	1927		
1928	1928		
1929	1929		
1930	1930		
1931	1931		
1932	1932		
1933	1933		
1934	1934		
1935	1935		
1936	1936		
1937	1937		
1938	1938		
1939	1939		
1940	1940		
1941	1941		
1942	1942		
1943	1943		
1944	1944		
1945	1945		
1946	1946		
1947	1947		
1948	1948		
1949	1949		
1950	1950		
1951	1951		
1952	1952		
1953	1953		
1954	1954		
1955	1955		
1956	1956		
1957	1957		
1958	1958		
1959	1959		
1960	1960		
1961	1961		
1962	1962		
1963	1963		
1964	1964		
1965	1965		
1966	1966		
1967	1967		
1968	1968		
1969	1969		
1970	1970		
1971	1971		
1972	1972		
1973	1973		
1974	1974		
1975	1975		
1976	1976		
1977	1977		
1978	1978		
1979	1979		
1980	1980		
1981	1981		
1982	1982		
1983	1983		
1984	1984		
1985	1985		
1986			

9/20

HIV-1 BRU 178 CONSTRUCTS, MUTATIONS, TRUNCATIONS		AA#	AA#																	
TRUNC.	PT.	REMOVED	AA#																	
		T20	MUTANTS	ADDED	AA#															
T4	X	X	X	NO AC-	Y	T	S	L	I	H	S	L	I	E	S	Q	E	K	NO	M2
T228	X				Y	T	S	L	I	H	S	L	I	E	S	Q	E	K		
T700					Y	I	S	L	I	H	S	L	I	E	S	Q	E	K		
T715	X				I	S	L	I	H	S	L	I	E	S	Q	E	K			
T65/T716	X				I	I	H	S	L	I	E	S	Q	E	K					
T714	X				I	I	H	S	L	I	E	S	Q	E	K					
T712	X				I	I	H	S	L	I	E	S	Q	E	K					
T64	X				I	I	H	S	L	I	E	S	Q	E	K					
T63	X				I	I	H	S	L	I	E	S	Q	E	K					
T62	X				I	I	H	S	L	I	E	S	Q	E	K					
T13	X		X		I	I	H	S	L	I	E	S	Q	E	K					
T61/T102	X				I	I	H	S	L	I	E	S	Q	E	K					
T217	X				I	I	H	S	L	I	E	S	Q	E	K					
T218	X				I	I	H	S	L	I	E	S	Q	E	K					
T219	X				I	I	H	S	L	I	E	S	Q	E	K					

FIG. 5B(1)

10/20

FIG.5B(II)

		HIV-1/1118 1C50(ng/ml)	
7	1	>400000	
1	7	>50000	
		>100000	
T4		ND	
T228		ND	
T110		ND	
T115		ND	
T65/T716		ND	
T714		ND	
T712		ND	
T64		ND	
T63		ND	
T62		ND	
T3		3000	
T61/T102		64000	
T217		40000	
T218		25000	
T219		48000	

SUBSTITUTE SHEET (RULE 26)

11/20

FIG. 5B

12/20

FIG. 5B (1)

**SUBSTITUTE SHEET (RULE 26)**

13/20

FIG. 5C

**SUBSTITUTE SHEET (RULE 26)**

14/20

Q1		Q2		Q3		Q4		Q5		Q6		Q7		Q8		Q9		Q10		Q11		Q12		Q13		Q14		Q15		Q16		Q17		Q18		Q19		Q20		Q21		Q22		Q23		Q24	
----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--	-----	--

FIG. 5C

**SUBSTITUTE SHEET (RULE 26)**

15/20

FIG. 5C

**SUBSTITUTE SHEET (RULE 26)**

16/20

W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T209	56
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T103	ND
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T212	3
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T213	25
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T214	19
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T215	23
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T216	1000
W	N	Q	E	K	N	E	D	K	W	A	S	L	W	N	W	F	T229	>100000
																	6	
																	4	
																	0.3	
																	3	
																	36	
																	0.5	
																	14	
																	68	
																	80000	
																	>100000	
																	>100000	

FIG.5C(IV)

SUBSTITUTE SHEET (RULE 26)

17/20

**SUBSTITUTE SHEET (RULE 26)**

18/20

		HIV/111B
		(C50) (μg/ml)
QARILAVERYLKDQ	QARILAVERYLKDQ	110
QARILAVERYLKDQ	QARILAVERYLKDQ	50
QARILAVERYLKDQ	QARILAVERYLKDQ	137
QARILAVERYLKDQ	QARILAVERYLKDQ	75*
QARILAVERYLKDQ	QARILAVERYLKDQ	148
QARILAVERYLKDQ	QARILAVERYLKDQ	83*
QARILAVERYLKDQ	QARILAVERYLKDQ	136
QARILAVERYLKDQ	QARILAVERYLKDQ	45*
QARILAVERYLKDQ	QARILAVERYLKDQ	18
QARILAVERYLKDQ	QARILAVERYLKDQ	50
QARILAVERYLKDQ	QARILAVERYLKDQ	133
QARILAVERYLKDQ	QARILAVERYLKDQ	>100*
QARILAVERYLKDQ	QARILAVERYLKDQ	121
QARILAVERYLKDQ	QARILAVERYLKDQ	2
QARILAVERYLKDQ	QARILAVERYLKDQ	186
QARILAVERYLKDQ	QARILAVERYLKDQ	2
QARILAVERYLKDQ	QARILAVERYLKDQ	11
QARILAVERYLKDQ	QARILAVERYLKDQ	>100
QARILAVERYLKDQ	QARILAVERYLKDQ	12
QARILAVERYLKDQ	QARILAVERYLKDQ	ND
QARILAV	QARILAV	17
QARILAV	QARILAV	26
QARILAV	QARILAV	134
QARILAV	QARILAV	>100*
QARILAV	QARILAV	16
QARILAV	QARILAV	44
QARILAV	QARILAV	135
QARILAV	QARILAV	>100*
QARILAV	QARILAV	55
QARILAV	QARILAV	13

FIG. 6(II)

SUBSTITUTE SHEET (RULE 26)

19/20

SINTIAN IMMUNODEFICIENCY VIRUS MD251		DP178-LIKE		TWO QEWEEKVKVDFLEENITALLEEAQIQQEKNM		YELQKLNSWDVFGNWF	
RESIDUE	245	246	247	248	249	250	251
I- 390	245	W	QEWEEKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 391	246	W	QEWEEKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 392	247	Q	EWEEKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 393	248	E	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 394	249	W	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 395	250	R	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 396	251	R	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 397	252	K	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 398	253	Y	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 399	254	D	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			
I- 400	255	E	WERKVKVDFLEENITALLEEAQIQQEKNM	YELQKLNSWDVFGNWF			

FIG. 7(1)

20/20

		ANTIVIRAL ACTIVITY	SIV
	RESIDUE	47	
291			
280		35	1390
281		35	1391
282		35	1392
283		35	1393
284		35	1394
285		35	1395
286		35	1396
287		35	1397
288		35	1398
289		35	1399
290		35	1400

FIG.7(II)

SUBSTITUTE SHEET (RULE 26)